<SEC-DOCUMENT>0001437749-23-032364.txt : 20231116
<SEC-HEADER>0001437749-23-032364.hdr.sgml : 20231116
<ACCEPTANCE-DATETIME>20231116171523
ACCESSION NUMBER:		0001437749-23-032364
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		19
CONFORMED PERIOD OF REPORT:	20231116
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20231116
DATE AS OF CHANGE:		20231116

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BioCardia, Inc.
		CENTRAL INDEX KEY:			0000925741
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				232753988
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38999
		FILM NUMBER:		231415535

	BUSINESS ADDRESS:	
		STREET 1:		320 SOQUEL WAY
		CITY:			SUNNYVALE
		STATE:			CA
		ZIP:			94085
		BUSINESS PHONE:		650-226-0123

	MAIL ADDRESS:	
		STREET 1:		320 SOQUEL WAY
		CITY:			SUNNYVALE
		STATE:			CA
		ZIP:			94085

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Tiger X Medical, Inc.
		DATE OF NAME CHANGE:	20110616

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Cardo Medical, Inc.
		DATE OF NAME CHANGE:	20081027

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CLICKNSETTLE COM INC
		DATE OF NAME CHANGE:	20000823
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>bcda20231116_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<XBRL>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:naics="http://xbrl.sec.gov/naics/2023" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:utreg="http://www.xbrl.org/2009/utr" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:us-roles="http://fasb.org/us-roles/2020-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:thunderdome="http://www.RDGFilings.com" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:rr="http://xbrl.sec.gov/rr/2018-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2023" xmlns:currency="http://xbrl.sec.gov/currency/2023" xmlns:exch="http://xbrl.sec.gov/exch/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:bcda="http://www.bcda.com/20231116"><head>
	<title>bcda20231116_8k.htm</title>

	<!-- Generated by ThunderDome Portal - 11/16/2023 8:26:13 PM -->
<meta http-equiv="Content-Type" content="text/html" /></head>
<body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;"><div style="display: none">
<ix:header>
<ix:hidden>
<ix:nonNumeric contextRef="d20238K" name="dei:AmendmentFlag">false</ix:nonNumeric>
<ix:nonNumeric contextRef="d20238K" name="dei:EntityCentralIndexKey">0000925741</ix:nonNumeric>

</ix:hidden>
<ix:references>
<link:schemaRef xlink:href="bcda-20231116.xsd" xlink:type="simple" />
</ix:references>
<ix:resources>
<xbrli:context id="d20238K">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000925741</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2023-11-16</xbrli:startDate>
<xbrli:endDate>2023-11-16</xbrli:endDate>
</xbrli:period>
</xbrli:context>

<xbrli:context id="d20238K_StatementClassOfStockAxis_CommonStock">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000925741</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bcda:CommonStockCustomMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2023-11-16</xbrli:startDate>
<xbrli:endDate>2023-11-16</xbrli:endDate>
</xbrli:period>
</xbrli:context>

<xbrli:context id="d20238K_StatementClassOfStockAxis_WarrantToPurchaseCommonStock">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000925741</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bcda:WarrantToPurchaseCommonStockCustomMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2023-11-16</xbrli:startDate>
<xbrli:endDate>2023-11-16</xbrli:endDate>
</xbrli:period>
</xbrli:context>



</ix:resources>
</ix:header>
</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>UNITED STATES</b></div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>SECURITIES AND EXCHANGE COMMISSION </b></div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Washington, D.C. 20549</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family: Times New Roman; font-size: 12pt; font-variant: normal; text-align: center; margin: 0pt;"><b>FORM <ix:nonNumeric contextRef="d20238K" name="dei:DocumentType"><b>8-K</b></ix:nonNumeric></b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>CURRENT REPORT</b></div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Date of Report (Date of earliest event reported): <ix:nonNumeric contextRef="d20238K" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate"><b>November 16, 2023</b></ix:nonNumeric></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="border-bottom:solid 1px #000000;vertical-align:middle;width:auto;">
			<div style="font-family: Times New Roman; font-size: 12pt; font-variant: normal; text-align: center; margin: 0pt;"><ix:nonNumeric contextRef="d20238K" name="dei:EntityRegistrantName"><b>BIOCARDIA, INC.</b></ix:nonNumeric></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:auto;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Exact name of registrant as specified in its charter)</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 36%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="d20238K" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode"><b>Delaware</b></ix:nonNumeric></div>
			</td>
			<td style="vertical-align: middle; width: 1%;">&#xa0;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 26%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="d20238K" name="dei:EntityFileNumber"><b>001-38999</b></ix:nonNumeric></div>
			</td>
			<td style="vertical-align: middle; width: 1%;">&#xa0;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 36%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="d20238K" name="dei:EntityTaxIdentificationNumber"><b>23-2753988</b></ix:nonNumeric></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 36%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(State or other jurisdiction</div>

			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">of incorporation)</div>
			</td>
			<td style="vertical-align: middle; width: 1%;">&#xa0;</td>
			<td style="vertical-align: middle; width: 26%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Commission</div>

			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">File Number)</div>
			</td>
			<td style="vertical-align: middle; width: 1%;">&#xa0;</td>
			<td style="vertical-align: middle; width: 36%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(IRS Employer</div>

			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Identification No.)</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="border-bottom:solid 1px #000000;vertical-align:middle;width:auto;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="d20238K" name="dei:EntityAddressAddressLine1"><b>320 Soquel Way</b></ix:nonNumeric>&#xa0;<br />
			<b><ix:nonNumeric contextRef="d20238K" name="dei:EntityAddressCityOrTown"><b>Sunnyvale</b></ix:nonNumeric>, <ix:nonNumeric contextRef="d20238K" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince"><b>California</b></ix:nonNumeric> <ix:nonNumeric contextRef="d20238K" name="dei:EntityAddressPostalZipCode"><b>94085</b></ix:nonNumeric></b></div>
			</td>
			<td style="vertical-align:middle;width:auto;">&#xa0;</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:auto;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Address of principal executive offices and zip code)</div>
			</td>
			<td style="vertical-align:middle;width:auto;">&#xa0;</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Registrant</b>&#8217;<b>s telephone number, including area code: (<ix:nonNumeric contextRef="d20238K" name="dei:CityAreaCode"><b>650</b></ix:nonNumeric>) <ix:nonNumeric contextRef="d20238K" name="dei:LocalPhoneNumber"><b>226-0120</b></ix:nonNumeric></b></div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<hr style="text-align: center; height: 1px; color: #000000; background-color: #000000; width: 25%; border: none; margin: 3pt auto" />
<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:top;width:auto;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><ix:nonNumeric contextRef="d20238K" format="ixt-sec:boolballotbox" name="dei:WrittenCommunications">&#9744;</ix:nonNumeric></div>
			</td>
			<td style="vertical-align:top;width:auto;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:top;width:auto;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><ix:nonNumeric contextRef="d20238K" format="ixt-sec:boolballotbox" name="dei:SolicitingMaterial">&#9744;</ix:nonNumeric></div>
			</td>
			<td style="vertical-align:top;width:auto;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:top;width:auto;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><ix:nonNumeric contextRef="d20238K" format="ixt-sec:boolballotbox" name="dei:PreCommencementTenderOffer">&#9744;</ix:nonNumeric></div>
			</td>
			<td style="vertical-align:top;width:auto;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:top;width:auto;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><ix:nonNumeric contextRef="d20238K" format="ixt-sec:boolballotbox" name="dei:PreCommencementIssuerTenderOffer">&#9744;</ix:nonNumeric></div>
			</td>
			<td style="vertical-align:top;width:auto;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Securities registered pursuant to Section 12(b) of the Act:</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 40%; border-left: 1px solid rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Title of each class</div>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 20%; border-left: 1px solid rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Trading Symbol(s)</div>
			</td>
			<td style="border-width: 1px; border-style: solid; border-color: rgb(0, 0, 0); vertical-align: middle; width: 40%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Name of each exchange on which registered</div>
			</td>
		</tr>
		<tr>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 40%; border-left: 1px solid rgb(0, 0, 0);">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="d20238K_StatementClassOfStockAxis_CommonStock" name="dei:Security12bTitle">Common Stock</ix:nonNumeric>, par value $0.001</div>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 20%; border-left: 1px solid rgb(0, 0, 0);">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="d20238K_StatementClassOfStockAxis_CommonStock" name="dei:TradingSymbol">BCDA</ix:nonNumeric></div>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 40%; border-left: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0);">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">The <ix:nonNumeric contextRef="d20238K_StatementClassOfStockAxis_CommonStock" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric> Capital Market</div>
			</td>
		</tr>
		<tr>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 40%; border-left: 1px solid rgb(0, 0, 0);">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="d20238K_StatementClassOfStockAxis_WarrantToPurchaseCommonStock" name="dei:Security12bTitle">Warrant to Purchase Common Stock</ix:nonNumeric></div>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 20%; border-left: 1px solid rgb(0, 0, 0);">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="d20238K_StatementClassOfStockAxis_WarrantToPurchaseCommonStock" name="dei:TradingSymbol">BCDAW</ix:nonNumeric></div>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 40%; border-left: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0);">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">The <ix:nonNumeric contextRef="d20238K_StatementClassOfStockAxis_WarrantToPurchaseCommonStock" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric> Capital Market</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR &#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR &#167;240.12b-2 of this chapter) <ix:nonNumeric contextRef="d20238K" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&#xa0;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#xa0;</div>
</div>
</div>
</div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Item 8.01 Other Events</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">On November 16, 2023, BioCardia, Inc. (the &#8220;Company&#8221;) entered into a securities purchase agreement (the &#8220;Purchase Agreement&#8221;) with a single healthcare-focused institutional investor pursuant to which the Company agreed to sell and issue to the investor 2,000,000 shares (the &#8220;Shares&#8221;) of the Company&#8217;s common stock, par value $0.001 per share (the &#8220;Common Stock&#8221;), in a registered direct offering (the &#8220;Offering&#8221;) at a price of $0.65 per share. The Offering is expected to close on or about November 20, 2023, subject to satisfaction of customary closing conditions.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The gross proceeds of the Offering will be approximately $1.3 million, before deducting placement agent fees and other offering expenses payable by the Company. The Company intends to use the net proceeds from the Offering for general corporate purposes, including but not limited to, advancing the Company&#8217;s investigational biotherapeutic candidates and the Company&#8217;s biotherapeutic delivery partnering business.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Shares were offered pursuant to the Company&#8217;s effective registration statement on Form S-3 and accompanying base prospectus (File No. 333-249426), previously filed with and declared effective by the Securities and Exchange Commission.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">H.C. Wainwright &amp; Co. (the &#8220;Placement Agent&#8221;) acted as the exclusive placement agent for the Offering. We have agreed to pay the Placement Agent a placement agent fee in an amount equal to seven percent 7% of the aggregate gross proceeds in the Offering, a management fee equal to 1% of the of the gross proceeds, and $75,000 for the Placement Agent&#8217;s legal and other out-of-pocket expenses.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Purchase Agreement contains customary representations, warranties and agreements by the Company, conditions to closing, indemnification obligations of the Company and investor, other obligations of the parties and termination provisions. The representations, warranties and covenants contained in the Purchase Agreement were made only for purposes of such agreement and as of specific dates, were solely for the benefit of the parties to such agreement, and may be subject to limitations agreed upon by the contracting parties.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The foregoing description of the Purchase Agreement is not complete and is qualified in its entirety by reference to the full text of the form of Purchase Agreement, a copy of which is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Item 9.01 Financial Statements and Exhibits.</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td colspan="3" style="vertical-align: bottom; width: 6%; border-bottom: 1px solid rgb(0, 0, 0);">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Exhibit</b></div>

			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Number</b></div>
			</td>
			<td colspan="3" style="vertical-align: middle; width: 1%;">&#xa0;</td>
			<td colspan="3" style="vertical-align: bottom; width: 93%; border-bottom: 1px solid rgb(0, 0, 0);">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Description</b></div>
			</td>
		</tr>
		<tr>
			<td colspan="3" style="vertical-align: top; width: 6%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">5.1</div>
			</td>
			<td colspan="3" style="vertical-align: top; width: 1%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>
			</td>
			<td colspan="3" style="vertical-align: top; width: 93%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="ex_598146.htm" style="-sec-extract:exhibit;">Opinion of Wilson Sonsini Goodrich &amp; Rosati.</a></div>
			</td>
		</tr>
		<tr>
			<td colspan="3" style="vertical-align: top; width: 6%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">23.1</div>
			</td>
			<td colspan="3" style="vertical-align: top; width: 1%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>
			</td>
			<td colspan="3" style="vertical-align: top; width: 93%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="ex_598146.htm" style="-sec-extract:exhibit;">Consent of Wilson Sonsini Goodrich &amp; Rosati (included in the opinion of Wilson Sonsini Goodrich &amp; Rosati filed as Exhibit 5.1 hereto).</a></div>
			</td>
		</tr>
		<tr>
			<td colspan="3" style="vertical-align: top; width: 6%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">99.1</div>
			</td>
			<td colspan="3" style="vertical-align: top; width: 1%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>
			</td>
			<td colspan="3" style="vertical-align: top; width: 93%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="ex_598147.htm" style="-sec-extract:exhibit;">Form of Securities Purchase Agreement, dated November 16, 2023, by and between the Company and each Purchaser party thereto.</a></div>
			</td>
		</tr>
		<tr>
			<td colspan="3" style="vertical-align: top; width: 6%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">104</div>
			</td>
			<td colspan="3" style="vertical-align: middle; width: 1%;">&#xa0;</td>
			<td colspan="3" style="vertical-align: top; width: 93%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Cover Page Interactive Data File (embedded within the Inline XBRL document).</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">-2-</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#xa0;</div>
</div>
</div>
</div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>SIGNATURES</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td colspan="3" style="vertical-align: middle; width: 42%;">&#xa0;</td>
			<td colspan="3" style="vertical-align: middle; width: 3%;">&#xa0;</td>
			<td colspan="3" style="vertical-align: bottom; width: 55%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>BIOCARDIA, INC.</b></div>
			</td>
		</tr>
		<tr>
			<td colspan="3" style="vertical-align: middle; width: 42%;">&#xa0;</td>
			<td colspan="3" style="vertical-align: middle; width: 3%;">&#xa0;</td>
			<td colspan="3" style="vertical-align: middle; width: 55%;">&#xa0;</td>
		</tr>
		<tr>
			<td colspan="3" style="vertical-align: bottom; width: 42%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Date: November 16, 2023</div>
			</td>
			<td colspan="3" style="vertical-align: top; width: 3%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">By:</div>
			</td>
			<td colspan="3" style="vertical-align: bottom; width: 55%; border-bottom: 1px solid rgb(0, 0, 0);">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">/s/ Peter Altman, Ph.D.</div>
			</td>
		</tr>
		<tr>
			<td colspan="3" style="vertical-align: middle; width: 42%;">&#xa0;</td>
			<td colspan="3" style="vertical-align: middle; width: 3%;">&#xa0;</td>
			<td colspan="3" style="vertical-align: top; width: 55%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Name: Peter Altman, Ph.D.</div>
			</td>
		</tr>
		<tr>
			<td colspan="3" style="vertical-align: middle; width: 42%;">&#xa0;</td>
			<td colspan="3" style="vertical-align: middle; width: 3%;">&#xa0;</td>
			<td colspan="3" style="vertical-align: top; width: 55%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Title: President and Chief Executive Officer</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center;">-3-</div>
</div>
</div>
</div>


</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>2
<FILENAME>ex_598146.htm
<DESCRIPTION>EXHIBIT 5.1
<TEXT>
<html><head>
	<title>ex_598146.htm</title>

	<!-- Generated by ThunderDome Portal - 11/16/2023 8:20:47 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;">
<p style="margin: 0px 0pt; text-align: right; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt"><b>Exhibit 5.1</b></font></p>

<p style="margin: 0px 0pt; text-align: left; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tr>
			<td style="width: 50%;">
			<div><img alt="image01.jpg" src="image01.jpg"></div>
			</td>
			<td style="width: 50%;">
			<div style="text-align: right;"><img alt="image02.jpg" src="image02.jpg"></div>
			</td>
		</tr>

</table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">November 16, 2023</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">BioCardia, Inc.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">320 Soquel Way</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Sunnyvale, California 94085</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align: top; width: 5%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"><b>Re:</b></p>
			</td>
			<td style="vertical-align: top; width: 95%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><u>Registered Direct Offering</u></b></p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Ladies and Gentlemen:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">We have acted as counsel to BioCardia Inc., a Delaware corporation (the &#8220;<u>Company</u>&#8221;), in connection with the registration of the offer and sale of 2,000,000 shares (the &#8220;<u>Shares</u>&#8221;) of the Company&#8217;s common stock, $0.001 par value per share (&#8220;<u>Common Stock</u>&#8221;), pursuant to the Company&#8217;s Registration Statement on Form S-3 (File No. 333-249426) initially filed on October 9, 2020 and declared effective by the Securities and Exchange Commission (the &#8220;<u>Commission</u>&#8221;) on October 20, 2020 (the &#8220;<u>Registration Statement</u>&#8221;).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The offering and sale of the Securities are being made pursuant to that certain Securities Purchase Agreement, dated as of November 16, 2023, by and between the Company and the purchaser identified in the signature pages thereto (the &#8220;<u>Securities Purchase Agreement</u>&#8221;).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">As such counsel, we have made such legal and factual examinations and inquiries as we have deemed necessary or advisable for the purpose of rendering the opinions and statements set forth below. In rendering the opinions and statements expressed below, we have examined originals or copies, certified or otherwise identified to our satisfaction, of such documents, corporate records, certificates of public officials and other instruments as we have deemed necessary for the purposes of rendering this opinion.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">In addition, we have reviewed originals or copies of such corporate records of the Company, certificates of public officials and such other documents which we consider necessary or advisable for the purpose of rendering the opinions set forth below. We have not independently established the facts stated therein.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">In our examination, we have assumed the genuineness of all signatures, the authenticity and completeness of all documents submitted to us as originals, the conformity with the originals of all documents submitted to us as copies, the authenticity of the originals of such documents and the legal competence of all signatories to such documents. We have also assumed the authority of such persons signing on behalf of the parties thereto other than the Company and the due authorization, execution and delivery of all documents by the parties thereto other than the Company. We have also assumed<i> </i>the conformity of the documents filed with the Commission via the Electronic Data Gathering, Analysis and Retrieval System (&#8220;<u>EDGAR</u>&#8221;), except for required EDGAR formatting changes, to physical copies submitted for our examination and the absence of any evidence extrinsic to the provisions of the written agreements between the parties that the parties intended a meaning contrary to that expressed by those provisions.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">On the basis of the foregoing, we are of the opinion that the Shares have been duly authorized by the Company and, when issued and delivered by the Company against payment therefor in accordance with the terms of and in the manner contemplated by the Securities Purchase Agreement and the Registration Statement, will be validly issued, fully paid and nonassessable.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">We express no opinion as to the laws of any other jurisdiction, other than the federal laws of the United States of America and the General Corporation Law of the State of Delaware.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&nbsp;</p>

<div style="text-align: center;"><img alt="image03.jpg" src="image03.jpg"></div>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%">&nbsp;</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
<div><img alt="image04.jpg" src="image04.jpg"></div>
</div>

<div style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&nbsp;</div>

<div style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&nbsp;</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">We consent to the use of this opinion as an exhibit to the Company&#8217;s Current Report on Form 8-K filed on or about the date hereof, for incorporation by reference into the Registration Statement. In giving this consent, we do not admit that we are in the category of persons whose consent is required under Section 7 of the Securities Act.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align: middle; width: 50%;">&nbsp;</td>
			<td style="vertical-align: middle; width: 50%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Very truly yours,</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 50%;">&nbsp;</td>
			<td style="vertical-align: middle; width: 50%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 50%;">&nbsp;</td>
			<td style="vertical-align: top; width: 50%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 11pt;text-indent:-11pt;">/s/ Wilson Sonsini Goodrich &amp; Rosati, P.C.</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 50%;">&nbsp;</td>
			<td style="vertical-align: top; width: 50%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 50%;">&nbsp;</td>
			<td style="vertical-align: top; width: 50%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">WILSON SONSINI GOODRICH &amp; ROSATI</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 50%;">&nbsp;</td>
			<td style="vertical-align: top; width: 50%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Professional Corporation</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>3
<FILENAME>ex_598147.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html><head>
	<title>ex_598147.htm</title>

	<!-- Generated by ThunderDome Portal - 11/16/2023 8:10:09 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size:10pt;font-family:'Times New Roman';padding:0in .1in;">
<p style="margin: 0px 0pt; text-align: right; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt"><b>Exhibit 99.1</b></font></p>

<p style="margin: 0px 0pt; text-align: left; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 36pt;text-indent:-36pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 36pt;text-indent:-36pt;"><b>FORM OF</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 36pt;text-indent:-36pt;"><b>SECURITIES PURCHASE AGREEMENT</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">This Securities Purchase Agreement (this &#8220;<u>Agreement</u>&#8221;) is dated as of November 16, 2023, between BioCardia, Inc., a Delaware corporation (the &#8220;<u>Company</u>&#8221;), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a &#8220;<u>Purchaser</u>&#8221; and collectively the &#8220;<u>Purchasers</u>&#8221;).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">WHEREAS, subject to the terms and conditions set forth in this Agreement and pursuant to an effective registration statement under the Securities Act (as defined below), the Company desires to issue and sell to each Purchaser, and each Purchaser, severally and not jointly, desires to purchase from the Company, securities of the Company as more fully described in this Agreement.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">NOW, THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Agreement, and for other good and valuable consideration the receipt and adequacy of which are hereby acknowledged, the Company and each Purchaser agree as follows:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b>ARTICLE I.</b></p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">DEFINITIONS</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">1.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Definitions</u>. In addition to the terms defined elsewhere in this Agreement, for all purposes of this Agreement, the following terms have the meanings set forth in this Section 1.1:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt;"><u>&#8220;Acquiring Person</u>&#8221; shall have the meaning ascribed to such term in Section 4.5.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;"><u>&#8220;Action</u>&#8221; shall have the meaning ascribed to such term in Section 3.1(j).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;"><u>&#8220;Affiliate</u>&#8221; means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control with a Person as such terms are used in and construed under Rule 405 under the Securities Act.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;"><u>&#8220;Board of Directors</u>&#8221; means the board of directors of the Company.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;"><u>&#8220;Business Day</u>&#8221; means any day other than Saturday, Sunday or other day on which commercial banks in The City of New York are authorized or required by law to remain closed; <u>provided</u>, <u>however</u>, for clarification, commercial banks shall not be deemed to be authorized or required by law to remain closed due to &#8220;stay at home&#8221;, &#8220;shelter-in-place&#8221;, &#8220;non-essential employee&#8221;&nbsp; or any other similar orders or restrictions or the closure of any physical branch locations at the direction of any governmental authority so long as the electronic funds transfer systems (including for wire transfers) of commercial banks in The City of New York generally open for use by customers on such day.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;"><u>&#8220;Closing</u>&#8221; means the closing of the purchase and sale of the Securities pursuant to Section 2.1.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;"><u>&#8220;Closing Date</u>&#8221; means the Trading Day on which all of the Transaction Documents have been executed and delivered by the applicable parties thereto, and all conditions precedent to (i) the Purchasers&#8217; obligations to pay the Subscription Amount and (ii) the Company&#8217;s obligations to deliver the Securities, in each case, have been satisfied or waived, but in no event later than the second (2<sup style="vertical-align:top;line-height:120%;">nd</sup>) Trading Day following the date hereof.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;"><u>&#8220;Commission</u>&#8221; means the United States Securities and Exchange Commission.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;"><u>&#8220;Common Stock</u>&#8221; means the common stock of the Company, par value $0.001 per share, and any other class of securities into which such securities may hereafter be reclassified or changed.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;"><u>&#8220;Common Stock Equivalents</u>&#8221; means any securities of the Company or the Subsidiaries which would entitle the holder thereof to acquire at any time Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant or other instrument that is at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;"><u>&#8220;Company Counsel</u>&#8221; means Wilson Sonsini Goodrich &amp; Rosati, P.C., with offices located at 650 Page Mill Road, Palo Alto, California 94304.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;"><u>&#8220;Disclosure Time</u>&#8221; means, (i) if this Agreement is signed on a day that is not a Trading Day or after 9:00 a.m. (New York City time) and before midnight (New York City time) on any Trading Day, 9:01 a.m. (New York City time) on the Trading Day immediately following the date hereof, unless otherwise instructed as to an earlier time by the Placement Agent, and (ii) if this Agreement is signed between midnight (New York City time) and 9:00 a.m. (New York City time) on any Trading Day, no later than 9:01 a.m. (New York City time) on the date hereof, unless otherwise instructed as to an earlier time by the Placement Agent.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;"><u>&#8220;EGS</u>&#8221; means Ellenoff Grossman &amp; Schole LLP, with offices located at 1345 Avenue of the Americas, New York, New York 10105-0302.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;"><u>&#8220;Evaluation Date</u>&#8221; shall have the meaning ascribed to such term in Section 3.1(s).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;"><u>&#8220;Exchange Act</u>&#8221; means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;"><u>&#8220;Exempt Issuance</u>&#8221; means the issuance of (a) shares of Common Stock or options to employees, officers or directors of the Company pursuant to any stock or option plan duly adopted for such purpose, by a majority of the non-employee members of the Board of Directors or a majority of the members of a committee of non-employee directors established for such purpose for services rendered to the Company, (b) securities upon the exercise or exchange of or conversion of securities exercisable or exchangeable for or convertible into shares of Common Stock issued and outstanding on the date of this Agreement, provided that such securities have not been amended since the date of this Agreement to increase the number of such securities or to decrease the exercise price, exchange price or conversion price of such securities (other than in connection with stock splits or combinations) or to extend the term of such securities, and (c) securities issued pursuant to acquisitions or strategic transactions approved by a majority of the disinterested directors of the Company, provided that such securities are issued as &#8220;restricted securities&#8221; (as defined in Rule 144) and carry no registration rights that require or permit the filing of any registration statement in connection therewith during the prohibition period in Section 4.11(a) herein, and provided that any such issuance shall only be to a Person (or to the equityholders of a Person) which is, itself or through its subsidiaries, an operating company or an owner of an asset in a business synergistic with the business of the Company and shall provide to the Company additional benefits in addition to the investment of funds, but shall not include a transaction in which the Company is issuing securities primarily for the purpose of raising capital or to an entity whose primary business is investing in securities.</p>

<div contenteditable="false" data-applyto="p" data-auto-pgnum="start" data-displaynum="2" data-fontname="Times New Roman" data-fontsize="10pt" data-numstyle="a" data-prefix="" data-startnum="2" data-suffix="" data-textalign="center">&nbsp;</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="2" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">2</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;"><u>&#8220;FCPA</u>&#8221; means the Foreign Corrupt Practices Act of 1977, as amended.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;"><u>&#8220;FDA</u>&#8221; shall have the meaning ascribed to such term in Section 3.1(hh).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;"><u>&#8220;FDCA</u>&#8221; shall have the meaning ascribed to such term in Section 3.1(hh).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;"><u>&#8220;GAAP</u>&#8221; shall have the meaning ascribed to such term in Section 3.1(h).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;"><u>&#8220;Indebtedness</u>&#8221; shall have the meaning ascribed to such term in Section 3.1(aa).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;"><u>&#8220;Intellectual Property Rights</u>&#8221; shall have the meaning ascribed to such term in Section 3.1(p).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;"><u>&#8220;Liens</u>&#8221; means a lien, charge, pledge, security interest, encumbrance, right of first refusal, preemptive right or other restriction.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;"><u>&#8220;Material Adverse Effect</u>&#8221; shall have the meaning assigned to such term in Section 3.1(b).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;"><u>&#8220;Material Permits</u>&#8221; shall have the meaning ascribed to such term in Section 3.1(n).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;"><u>&#8220;Per Share Purchase Price</u>&#8221; equals $_______, subject to adjustment for reverse and forward stock splits, stock dividends, stock combinations and other similar transactions of the Common Stock that occur after the date of this Agreement.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;"><u>&#8220;Person</u>&#8221; means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;"><u>&#8220;Pharmaceutical Product</u>&#8221; shall have the meaning ascribed to such term in Section 3.1(hh).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;"><u>&#8220;Placement Agent</u>&#8221; means H.C. Wainwright &amp; Co., LLC.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="3" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">3</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;"><u>&#8220;Proceeding</u>&#8221; means an action, claim, suit, investigation or proceeding (including, without limitation, an informal investigation or partial proceeding, such as a deposition), whether commenced or threatened.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;"><u>&#8220;Prospectus</u>&#8221; means the final prospectus filed for the Registration Statement.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;"><u>&#8220;Prospectus Supplement</u>&#8221; means the supplement to the Prospectus complying with Rule 424(b) of the Securities Act that is filed with the Commission and delivered by the Company to each Purchaser at the Closing.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;"><u>&#8220;Purchaser Party</u>&#8221; shall have the meaning ascribed to such term in Section 4.8.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;"><u>&#8220;Registration Statement</u>&#8221; means the effective registration statement with Commission file No. 333-249426 which registers the sale of the Shares to the Purchasers.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;"><u>&#8220;Required Approvals</u>&#8221; shall have the meaning ascribed to such term in Section 3.1(e).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;"><u>&#8220;Rule 144</u>&#8221; means Rule 144 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect as such Rule.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;"><u>&#8220;Rule 424</u>&#8221; means Rule 424 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect as such Rule.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;"><u>&#8220;SEC Reports</u>&#8221; shall have the meaning ascribed to such term in Section 3.1(h).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;"><u>&#8220;Securities</u>&#8221; means the Shares.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">&#8220;<u>Securities Act</u>&#8221; means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;"><u>&#8220;Shares</u>&#8221; means the shares of Common Stock issued or issuable to each Purchaser pursuant to this Agreement.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;"><u>&#8220;Short Sales</u>&#8221; means all &#8220;short sales&#8221; as defined in Rule 200 of Regulation SHO under the Exchange Act (but shall not be deemed to include locating and/or borrowing shares of Common Stock).&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;"><u>&#8220;Subscription Amount</u>&#8221; means, as to each Purchaser, the aggregate amount to be paid for Shares purchased hereunder as specified below such Purchaser&#8217;s name on the signature page of this Agreement and next to the heading &#8220;Subscription Amount,&#8221; in United States dollars and in immediately available funds.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="4" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">4</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;"><u>&#8220;Subsidiary</u>&#8221; shall have the meaning ascribed to such term in Section 3.1(a).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;"><u>&#8220;Trading Day</u>&#8221; means a day on which the principal Trading Market is open for trading.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;"><u>&#8220;Trading Market</u>&#8221; means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market or the New York Stock Exchange (or any successors to any of the foregoing).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;"><u>&#8220;Transaction Documents</u>&#8221; means this Agreement, all exhibits and schedules thereto and hereto and any other documents or agreements executed in connection with the transactions contemplated hereunder.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;"><u>&#8220;Transfer Agent</u>&#8221; means Continental Stock Transfer &amp; Trust Company, the current transfer agent of the Company, and any successor transfer agent of the Company.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b>ARTICLE II.</b></p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">PURCHASE AND SALE</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">2.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Closing</u>. On the Closing Date, upon the terms and subject to the conditions set forth herein, the Company agrees to sell, and the Purchasers, severally and not jointly, agree to purchase, up to an aggregate of $_______ of Shares. Each Purchaser&#8217;s Subscription Amount as set forth on the signature page hereto executed by such Purchaser shall be made available for &#8220;Delivery Versus Payment&#8221; settlement with the Company or its designee. The Company shall deliver to each Purchaser its respective Shares, as determined pursuant to Section 2.2(a), and the Company and each Purchaser shall deliver the other items set forth in Section 2.2 deliverable at the Closing. Upon satisfaction of the covenants and conditions set forth in Sections 2.2 and 2.3, the Closing shall take place remotely by electronic transfer of the Closing documentation. Unless otherwise directed by the Placement Agent, settlement of the Shares shall occur via &#8220;Delivery Versus Payment&#8221; (&#8220;DVP&#8221;)<i> </i>(i.e., on the Closing Date, the Company shall issue the Shares registered in the Purchasers&#8217; names and addresses and released by the Transfer Agent directly to the account(s) at the Placement Agent identified by each Purchaser; upon receipt of such Shares, the Placement Agent shall promptly electronically deliver such Shares to the applicable Purchaser, and payment therefor shall be made by the Placement Agent (or its clearing firm) by wire transfer to the Company). Notwithstanding anything herein to the contrary, if at any time on or after the time of execution of this Agreement by the Company and an applicable Purchaser, through, and including the time immediately prior to the Closing (the &#8220;<u>Pre-Settlement Period</u>&#8221;), such Purchaser sells to any Person all, or any portion, of the Shares to be issued hereunder to such Purchaser at the Closing (collectively, the &#8220;<u>Pre-Settlement Shares</u>&#8221;), such Purchaser shall, automatically hereunder (without any additional required actions by such Purchaser or the Company), be deemed to be unconditionally bound to purchase, such Pre-Settlement Shares at the Closing; provided, that the Company shall not be required to deliver any Pre-Settlement Shares to such Purchaser prior to the Company&#8217;s receipt of the purchase price of such Pre-Settlement Shares hereunder; and provided further that the Company hereby acknowledges and agrees that the forgoing shall not constitute a representation or covenant by such Purchaser as to whether or not during the Pre-Settlement Period such Purchaser shall sell any shares of Common Stock to any Person and that any such decision to sell any shares of Common Stock by such Purchaser shall solely be made at the time such Purchaser elects to effect any such sale, if any.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="5" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">5</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">2.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Deliveries</u>.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">(a)&nbsp;&nbsp;&nbsp;&nbsp;On or prior to the Closing Date (except as indicated below), the Company shall deliver or cause to be delivered to each Purchaser the following:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 72pt; text-indent: 36pt; text-align: justify;">(i)&nbsp;&nbsp;&nbsp;&nbsp;this Agreement duly executed by the Company;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 72pt; text-indent: 36pt; text-align: justify;">(ii)&nbsp;&nbsp;&nbsp;&nbsp;a legal opinion of Company Counsel, in form and substance reasonably satisfactory to the Placement Agent;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 72pt; text-indent: 36pt; text-align: justify;">(iii)&nbsp;&nbsp;&nbsp;&nbsp;subject to Section 2.1, the Company shall have provided each Purchaser with the Company&#8217;s wire instructions, on Company letterhead and executed by the Chief Executive Officer or Chief Financial Officer;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 72pt; text-indent: 36pt; text-align: justify;">(iv)&nbsp;&nbsp;&nbsp;&nbsp;subject to Section 2.1, a copy of the irrevocable instructions to the Transfer Agent instructing the Transfer Agent to deliver on an expedited basis via The Depository Trust Company Deposit or Withdrawal at Custodian system (&#8220;<u>DWAC</u>&#8221;) Shares equal to such Purchaser&#8217;s Subscription Amount divided by the Per Share Purchase Price, registered in the name of such Purchaser; and</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 72pt; text-indent: 36pt; text-align: justify;">(v)&nbsp;&nbsp;&nbsp;&nbsp;the Prospectus and Prospectus Supplement (which may be delivered in accordance with Rule 172 under the Securities Act).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">(b)&nbsp;&nbsp;&nbsp;&nbsp;On or prior to the Closing Date, each Purchaser shall deliver or cause to be delivered to the Company the following:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 72pt; text-indent: 36pt; text-align: justify;">(i)&nbsp;&nbsp;&nbsp;&nbsp;this Agreement duly executed by such Purchaser; and</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 72pt; text-indent: 36pt; text-align: justify;">(ii)&nbsp;&nbsp;&nbsp;&nbsp;such Purchaser&#8217;s Subscription Amount, which shall be made available for &#8220;Delivery Versus Payment&#8221; settlement with the Company or its designee.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">2.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Closing Conditions</u>.<u> </u></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The obligations of the Company hereunder in connection with the Closing are subject to the following conditions being met:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 72pt; text-indent: 36pt; text-align: justify;">(i)&nbsp;&nbsp;&nbsp;&nbsp;the accuracy in all material respects (or, to the extent representations or warranties are qualified by materiality, in all respects) on the Closing Date of the representations and warranties of the Purchasers contained herein (unless as of a specific date therein in which case they shall be accurate in all material respects (or, to the extent representations or warranties are qualified by materiality, in all respects) as of such date);</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="6" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">6</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 72pt; text-indent: 36pt; text-align: justify;">(ii)&nbsp;&nbsp;&nbsp;&nbsp;all obligations, covenants and agreements of each Purchaser required to be performed at or prior to the Closing Date shall have been performed; and</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 72pt; text-indent: 36pt; text-align: justify;">(iii)&nbsp;&nbsp;&nbsp;&nbsp;the delivery by each Purchaser of the items set forth in Section 2.2(b) of this Agreement.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">(b)&nbsp;&nbsp;&nbsp;&nbsp;The respective obligations of the Purchasers hereunder in connection with the Closing are subject to the following conditions being met:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 72pt; text-indent: 36pt; text-align: justify;">(i)&nbsp;&nbsp;&nbsp;&nbsp;the accuracy in all material respects (or, to the extent representations or warranties are qualified by materiality or Material Adverse Effect, in all respects) when made and on the Closing Date of the representations and warranties of the Company contained herein (unless as of a specific date therein in which case they shall be accurate in all material respects or, to the extent representations or warranties are qualified by materiality or Material Adverse Effect, in all respects) as of such date);</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 72pt; text-indent: 36pt; text-align: justify;">(ii)&nbsp;&nbsp;&nbsp;&nbsp;all obligations, covenants and agreements of the Company required to be performed at or prior to the Closing Date shall have been performed;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 72pt; text-indent: 36pt; text-align: justify;">(iii)&nbsp;&nbsp;&nbsp;&nbsp;the delivery by the Company of the items set forth in Section 2.2(a) of this Agreement;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 72pt; text-indent: 36pt; text-align: justify;">(iv)&nbsp;&nbsp;&nbsp;&nbsp;there shall have been no Material Adverse Effect with respect to the Company since the date hereof; and</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 72pt; text-indent: 36pt; text-align: justify;">(v)&nbsp;&nbsp;&nbsp;&nbsp;from the date hereof to the Closing Date, trading in the Common Stock shall not have been suspended by the Commission or the Company&#8217;s principal Trading Market, and, at any time prior to the Closing Date, trading in securities generally as reported by Bloomberg L.P. shall not have been suspended or limited, or minimum prices shall not have been established on securities whose trades are reported by such service, or on any Trading Market, nor shall a banking moratorium have been declared either by the United States or New York State authorities nor shall there have occurred any material outbreak or escalation of hostilities or other national or international calamity of such magnitude in its effect on, or any material adverse change in, any financial market which, in each case, in the reasonable judgment of such Purchaser, makes it impracticable or inadvisable to purchase the Securities at the Closing.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="7" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">7</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b>ARTICLE III.</b></p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">REPRESENTATIONS AND WARRANTIES</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">3.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Representations and Warranties of the Company</u>. The Company hereby makes the following representations and warranties to each Purchaser:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Subsidiaries</u>. The Company owns, directly or indirectly, all of the capital stock or other equity interests of each subsidiary that constitutes a &#8220;significant subsidiary&#8221; as defined in Rule 1-02 of Regulation S-X under the Exchange Act (individually, a &#8220;Subsidiary&#8221;) free and clear of any Liens (which for purposes of this Agreement shall mean a lien, charge, security interest, encumbrance, right of first refusal, preemptive right or other restriction), and all of the issued and outstanding shares of capital stock of each Subsidiary are validly issued and are fully paid, non-assessable and free of preemptive and similar rights to subscribe for or purchase securities.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Organization and Qualification</u>. The Company and each of the Subsidiaries is an entity duly incorporated or otherwise organized, validly existing and in good standing under the laws of the jurisdiction of its incorporation or organization, with the requisite power and authority to own and use its properties and assets and to carry on its business as currently conducted. Neither the Company nor any Subsidiary is in violation nor default of any of the provisions of its respective certificate or articles of incorporation, bylaws or other organizational or charter documents. Each of the Company and the Subsidiaries is duly qualified to conduct business and is in good standing as a foreign corporation or other entity in each jurisdiction in which the nature of the business conducted or property owned by it makes such qualification necessary, except where the failure to be so qualified or in good standing, as the case may be, would not have or reasonably be expected to result in: (i) a material adverse effect on the legality, validity or enforceability of any Transaction Document, (ii) a material adverse effect on the results of operations, assets, business, prospects or condition (financial or otherwise) of the Company and the Subsidiaries, taken as a whole, or (iii) a material adverse effect on the Company&#8217;s ability to perform in any material respect on a timely basis its obligations under any Transaction Document (any of (i), (ii) or (iii), a &#8220;<u>Material Adverse Effect</u>&#8221;) and no Proceeding has been instituted in any such jurisdiction revoking, limiting or curtailing or seeking to revoke, limit or curtail such power and authority or qualification.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Authorization; Enforcement</u>. The Company has the requisite corporate power and authority to enter into and to consummate the transactions contemplated by this Agreement and each of the other Transaction Documents and otherwise to carry out its obligations hereunder and thereunder. The execution and delivery of this Agreement and each of the other Transaction Documents by the Company and the consummation by it of the transactions contemplated hereby and thereby have been duly authorized by all necessary action on the part of the Company and no further action is required by the Company, the Board of Directors or the Company&#8217;s stockholders in connection herewith or therewith other than in connection with the Required Approvals. This Agreement and each other Transaction Document to which the Company is a party has been (or upon delivery will have been) duly executed by the Company and, when delivered in accordance with the terms hereof and thereof, will constitute the valid and binding obligation of the Company enforceable against the Company in accordance with its terms, except (i) as limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application affecting enforcement of creditors&#8217; rights generally, (ii) as limited by laws relating to the availability of specific performance, injunctive relief or other equitable remedies and (iii) insofar as indemnification and contribution provisions may be limited by applicable law.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="8" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">8</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>No Conflicts</u>. The execution, delivery and performance by the Company of this Agreement and the other Transaction Documents to which it is a party, the issuance and sale of the Securities and the consummation by the Company of the transactions contemplated hereby and thereby do not and will not (i) conflict with or violate any provision of the Company&#8217;s or any Subsidiary&#8217;s certificate or articles of incorporation, bylaws or other organizational or charter documents, or (ii) conflict with, or constitute a default (or an event that with notice or lapse of time or both would become a default) under, result in the creation of any Lien upon any of the properties or assets of the Company or any Subsidiary, or give to others any rights of termination, amendment, anti-dilution or similar adjustments, acceleration or cancellation (with or without notice, lapse of time or both) of, any agreement, credit facility, debt or other instrument (evidencing a Company or Subsidiary debt or otherwise) or other understanding to which the Company or any Subsidiary is a party or by which any property or asset of the Company or any Subsidiary is bound or affected, or (iii) subject to the Required Approvals, conflict with or result in a violation of any law, rule, regulation, order, judgment, injunction, decree or other restriction of any court or governmental authority to which the Company or a Subsidiary is subject (including federal and state securities laws and regulations), or by which any property or asset of the Company or a Subsidiary is bound or affected; except in the case of each of clauses (ii) and (iii), such as would not have or reasonably be expected to result in a Material Adverse Effect.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Filings, Consents and Approvals</u>. The Company is not required to obtain any consent, waiver, authorization or order of, give any notice to, or make any filing or registration with, any court or other federal, state, local or other governmental authority or other Person in connection with the execution, delivery and performance by the Company of this Agreement and the other Transaction Documents, other than: (i) the filings required pursuant to Section 4.4 of this Agreement, (ii) the filing with the Commission of the Prospectus Supplement, (iii) application(s) to each applicable Trading Market for the listing of the Shares for trading thereon in the time and manner required thereby and (iv) such filings as are required to be made under applicable state securities laws (collectively, the &#8220;<u>Required Approvals</u>&#8221;).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="9" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">9</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Issuance of the Securities; Registration</u>. The Securities are duly authorized and, when issued and paid for in accordance with the applicable Transaction Documents, will be duly and validly issued, fully paid and nonassessable, free and clear of all Liens imposed by the Company. The Company has reserved from its duly authorized capital stock a sufficient number of shares of Common Stock issuable pursuant to this Agreement. The Company has prepared and filed the Registration Statement in conformity with the requirements of the Securities Act, which became effective on&nbsp;October 20, 2020 (the &#8220;<u>Effective Date</u>&#8221;), including the Prospectus, and such amendments and supplements thereto as may have been required to the date of this Agreement. The Registration Statement is effective under the Securities Act and no stop order preventing or suspending the effectiveness of the Registration Statement or suspending or preventing the use of the Prospectus has been issued by the Commission and no proceedings for that purpose have been instituted or, to the knowledge of the Company, are threatened by the Commission. The Company, if required by the rules and regulations of the Commission, shall file the Prospectus with the Commission pursuant to Rule 424(b). At the time the Registration Statement and any amendments thereto became effective, at the date of this Agreement and at the Closing Date, the Registration Statement and any amendments thereto conformed and will conform in all material respects to the requirements of the Securities Act and did not and will not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary to make the statements therein not misleading; and the Prospectus and any amendments or supplements thereto, at the time the Prospectus or any amendment or supplement thereto was issued and at the Closing Date, conformed and will conform in all material respects to the requirements of the Securities Act and did not and will not contain an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading. The Company was at the time of the filing of the Registration Statement eligible to use Form S-3. The Company is eligible to use Form S-3 under the Securities Act and it meets the transaction requirements with respect to the aggregate market value of securities being sold pursuant to this offering and during the twelve (12) months prior to this offering, as set forth in General Instruction I.B.6 of Form S-3.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Capitalization</u>. The authorized capital stock of the Company conforms to the description thereof set forth in the Registration Statement and the Prospectus. Except as disclosed in the SEC Reports and except as pursuant to this Agreement, the Company has not issued any capital stock since its most recently filed periodic report under the Exchange Act, other than pursuant to the exercise of employee stock options and the vesting of restricted stock awards under the Company&#8217;s equity incentive plans, the issuance of shares of Common Stock or stock options to employees and consultants pursuant to the Company&#8217;s equity incentive plans or employee stock purchase plans and pursuant to the conversion and/or exercise of Common Stock Equivalents outstanding as of the date of the most recently filed periodic report under the Exchange Act. No Person has any right of first refusal, preemptive right, right of participation, or any similar right to participate in the transactions contemplated by the Transaction Documents. Except as a result of the purchase and sale of the Securities and as set forth in the SEC Reports, there are no outstanding options, warrants, scrip rights to subscribe to, calls or commitments of any character whatsoever relating to, or securities, rights or obligations convertible into or exercisable or exchangeable for, or giving any Person any right to subscribe for or acquire, any shares of Common Stock or the capital stock of any Subsidiary, or contracts, commitments, understandings or arrangements by which the Company or any Subsidiary is or may become bound to issue additional shares of Common Stock or Common Stock Equivalents or capital stock of any Subsidiary. The issuance and sale of the Securities will not obligate the Company or any Subsidiary to issue shares of Common Stock or other securities to any Person (other than the Purchasers). There are no outstanding securities or instruments of the Company or any Subsidiary with any provision that adjusts the exercise, conversion, exchange or reset price of such security or instrument upon an issuance of securities by the Company or any Subsidiary. There are no outstanding securities or instruments of the Company or any Subsidiary that contain any redemption or similar provisions, and there are no contracts, commitments, understandings or arrangements by which the Company or any Subsidiary is or may become bound to redeem a security of the Company or such Subsidiary. The Company does not have any stock appreciation rights or &#8220;phantom stock&#8221; plans or agreements or any similar plan or agreement. All of the outstanding shares of capital stock of the Company are duly authorized, validly issued, fully paid and nonassessable, have been issued in compliance with all federal and state securities laws, and none of such outstanding shares was issued in violation of any preemptive rights or similar rights to subscribe for or purchase securities. No further approval or authorization of any stockholder, the Board of Directors or others is required for the issuance and sale of the Securities. There are no stockholders agreements, voting agreements or other similar agreements with respect to the Company&#8217;s capital stock to which the Company is a party or, to the knowledge of the Company, between or among any of the Company&#8217;s stockholders.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="10" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">10</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>SEC Reports; Financial Statements</u>. The Company has filed all reports, schedules, forms, statements and other documents required to be filed by the Company under the Securities Act and the Exchange Act, including pursuant to Section 13(a) or 15(d) thereof, for the one year preceding the date hereof (or such shorter period as the Company was required by law or regulation to file such material) (the foregoing materials, including the exhibits thereto and documents incorporated by reference therein, together with the Prospectus and the Prospectus Supplement, being collectively referred to herein as the &#8220;<u>SEC Reports</u>&#8221;) on a timely basis or has received a valid extension of such time of filing and has filed any such SEC Reports prior to the expiration of any such extension. As of their respective dates, the SEC Reports complied in all material respects with the requirements of the Securities Act and the Exchange Act, as applicable, and, since December 31, 2022 (including, without limitation, the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2022), none of the SEC Reports, when filed, contained any untrue statement of a material fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading. The financial statements of the Company included in the SEC Reports comply in all material respects with applicable accounting requirements and the rules and regulations of the Commission with respect thereto as in effect at the time of filing. Such financial statements have been prepared in accordance with United States generally accepted accounting principles applied on a consistent basis during the periods involved (&#8220;<u>GAAP</u>&#8221;), except as may be otherwise specified in such financial statements or the notes thereto and except that unaudited financial statements may not contain all footnotes required by GAAP, and fairly present in all material respects the financial position of the Company and its consolidated Subsidiaries as of and for the dates thereof and the results of operations and cash flows for the periods then ended, subject, in the case of unaudited statements, to normal, immaterial, year-end audit adjustments.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="11" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">11</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Material Changes; Undisclosed Events, Liabilities or Developments</u>. Since the date of the latest audited financial statements included within the SEC Reports, except as set forth in the SEC Reports, (i) there has been no event, occurrence or development that has had or that would reasonably be expected to result in a Material Adverse Effect, (ii) the Company has not incurred any liabilities (contingent or otherwise) other than (A) trade payables and accrued expenses incurred in the ordinary course of business consistent with past practice and (B) liabilities not required to be reflected in the Company&#8217;s financial statements pursuant to GAAP or disclosed in filings made with the Commission, (iii) the Company has not altered its method of accounting, (iv) the Company has not declared or made any dividend or distribution of cash or other property to its stockholders or purchased, redeemed or made any agreements to purchase or redeem any shares of its capital stock and (v) the Company has not issued any equity securities to any officer, director or Affiliate, except pursuant to existing Company equity incentive plans. The Company does not have pending before the Commission any request for confidential treatment of information. Except for the issuance of the Securities contemplated by this Agreement or as set forth in the SEC Reports, no event, liability, fact, circumstance, occurrence or development has occurred or exists or is reasonably expected to occur or exist with respect to the Company or its Subsidiaries or their respective businesses, prospects, properties, operations, assets or financial condition that would be required to be disclosed by the Company under applicable securities laws at the time this representation is made or deemed made that has not been publicly disclosed at least 1 Trading Day prior to the date that this representation is made.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">(j)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Litigation</u>. Except as set forth in the SEC Reports, there is no action, suit, inquiry, notice of violation, proceeding or investigation pending or, to the knowledge of the Company, threatened against or affecting the Company, any Subsidiary or any of their respective properties before or by any court, arbitrator, governmental or administrative agency or regulatory authority (federal, state, county, local or foreign) (collectively, an &#8220;<u>Action</u>&#8221;), which, (i) adversely affects or challenges the legality, validity or enforceability of any of the Transaction Documents or the issuance of the Securities hereunder or (ii) would, if there were an unfavorable decision, have or reasonably be expected to result in a Material Adverse Effect. Except as set forth in the SEC Reports, neither the Company nor any Subsidiary, nor any director or officer thereof, is or has been the subject of any Action involving a claim of violation of or liability under federal or state securities laws or a claim of breach of fiduciary duty that is required to be set forth in the SEC Reports which (i) adversely affects or challenges the legality, validity or enforceability of this Agreement or the issuance of the Shares hereunder or (ii) would, if there were an unfavorable decision, have or reasonably be expected to result in a Material Adverse Effect. Except as set forth in the SEC Reports, there has not been, and to the knowledge of the Company, there is not pending or contemplated, any investigation by the Commission involving the Company or any current or former director or officer of the Company. The Commission has not issued any stop order or other order suspending the effectiveness of any registration statement filed by the Company or any Subsidiary under the Exchange Act or the Securities Act.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="12" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">12</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">(k)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Labor Relations</u>. No labor dispute exists or, to the knowledge of the Company, is imminent with respect to any of the employees of the Company, which would reasonably be expected to result in a Material Adverse Effect. None of the Company&#8217;s or its Subsidiaries&#8217; employees is a member of a union that relates to such employee&#8217;s relationship with the Company or such Subsidiary, and neither the Company nor any of its Subsidiaries is a party to a collective bargaining agreement, and the Company and its Subsidiaries believe that their relationships with their employees are good. To the knowledge of the Company, no executive officer of the Company or any Subsidiary, is, or is now expected to be, in violation of any material term of any employment contract, confidentiality, disclosure or proprietary information agreement or non-competition agreement, or any other contract or agreement or any restrictive covenant in favor of any third party, and the continued employment of each such executive officer does not subject the Company or any of its Subsidiaries to any liability with respect to any of the foregoing matters. The Company and its Subsidiaries are in compliance with all applicable U.S. federal, state, local and foreign laws and regulations relating to employment and employment practices, terms and conditions of employment and wages and hours, except where the failure to be in compliance would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">(l)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Compliance</u>. Except as set forth in the SEC Reports, neither the Company nor any Subsidiary: (i) is in default under or in violation of (and no event has occurred that has not been waived that, with notice or lapse of time or both, would result in a default by the Company or any Subsidiary under), nor has the Company or any Subsidiary received notice of a claim that it is in default under or that it is in violation of, any indenture, loan or credit agreement or any other agreement or instrument to which it is a party or by which it or any of its properties is bound (whether or not such default or violation has been waived), (ii) is in violation of any judgment, decree or order of any court, arbitrator or other governmental authority or (iii) is or has been in violation of any statute, rule, ordinance or regulation of any governmental authority, including without limitation all foreign, federal, state and local laws relating to taxes, environmental protection, occupational health and safety, product quality and safety and employment and labor matters, except in each case as would not have or reasonably be expected to result in a Material Adverse Effect.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">(m)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Environmental Laws</u>.The Company and its Subsidiaries (i) are in compliance with all federal, state, local and foreign laws relating to pollution or protection of human health or the environment (including ambient air, surface water, groundwater, land surface or subsurface strata), including laws relating to emissions, discharges, releases or threatened releases of chemicals, pollutants, contaminants, or toxic or hazardous substances or wastes (collectively, &#8220;<u>Hazardous Materials</u>&#8221;) into the environment, or otherwise relating to the manufacture, processing, distribution, use, treatment, storage, disposal, transport or handling of Hazardous Materials, as well as all authorizations, codes, decrees, demands, or demand letters, injunctions, judgments, licenses, notices or notice letters, orders, permits, plans or regulations, issued, entered, promulgated or approved thereunder (&#8220;<u>Environmental Laws</u>&#8221;); (ii) have received all permits licenses or other approvals required of them under applicable Environmental Laws to conduct their respective businesses; and (iii) are in compliance with all terms and conditions of any such permit, license or approval where in each clause (i), (ii) and (iii), the failure to so comply would be reasonably expected to have, individually or in the aggregate, a Material Adverse Effect.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="13" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">13</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">(n)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Regulatory Permits</u>. The Company and the Subsidiaries possess all certificates, authorizations and permits issued by the appropriate federal, state, local or foreign regulatory authorities necessary to conduct their respective businesses as described in the SEC Reports, except where the failure to possess such permits would not reasonably be expected to result in a Material Adverse Effect (&#8220;<u>Material Permits</u>&#8221;), and neither the Company nor any Subsidiary has received any notice of proceedings relating to the revocation or modification of any Material Permit.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">(o)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Title to Assets</u>. The Company and the Subsidiaries have good and marketable title in fee simple to all real property owned by them and good and marketable title in all personal property owned by them that is material to the business of the Company and the Subsidiaries, in each case free and clear of all Liens, except for (i) Liens as do not materially affect the value of such property and do not materially interfere with the use made and proposed to be made of such property by the Company and the Subsidiaries and (ii) Liens for the payment of federal, state or other taxes, for which appropriate reserves have been made therefor in accordance with GAAP and, the payment of which is neither delinquent nor subject to penalties. Any real property and facilities held under lease by the Company and the Subsidiaries are held by them under valid, subsisting and enforceable leases with which the Company and the Subsidiaries are in compliance.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">(p)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Intellectual Property</u>. To the Company&#8217;s knowledge, the Company and the Subsidiaries have, or have rights to use, all patents, patent applications, trademarks, trademark applications, service marks, trade names, trade secrets, inventions, copyrights, licenses and other intellectual property rights and similar rights owned or licensed by the Company or the Subsidiaries and necessary or required for use in connection with their respective businesses as described in the SEC Reports since December 31, 2022 (including, without limitation, the Company&#8217;s annual report on Form 10-K for the fiscal year ended December 31, 2022) and which the failure to do so have would have a Material Adverse Effect (collectively, the &#8220;<u>Intellectual Property Rights</u>&#8221;). None of, and neither the Company nor any Subsidiary has received a notice (written or otherwise) that any of, the Intellectual Property Rights has expired, terminated or been abandoned, or is expected to expire or terminate or be abandoned, within two (2) years from the date of this Agreement, except for expirations, terminations or abandonments which would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. Neither the Company nor any Subsidiary has received, since the date of the latest audited financial statements included within the SEC Reports, a written notice of a claim that the operation of their businesses violate or infringe upon the rights, including, without limitation, the Intellectual Property Rights of any Person, except as would not have or reasonably be expected to not have a Material Adverse Effect. To the knowledge of the Company, all such Intellectual Property Rights are enforceable and there is no existing infringement by another Person of any of the Intellectual Property Rights. The Company and its Subsidiaries have taken reasonable security measures to protect the secrecy, confidentiality and value of all of their Intellectual Property Rights, except where failure to do so would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="14" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">14</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">(q)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Insurance</u>. The Company and the Subsidiaries are insured by insurers of recognized financial responsibility against such losses and risks and in such amounts as are prudent and customary in the businesses in which the Company and the Subsidiaries are engaged, including, but not limited to, directors and officers insurance coverage. Neither the Company nor any Subsidiary has any reason to believe that it will not be able to renew its existing insurance coverage as and when such coverage expires or to obtain similar coverage from similar insurers as may be necessary to continue its business without a significant increase in cost.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">(r)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Transactions With Affiliates and Employees</u>. Except as set forth in the SEC Reports, none of the officers or directors of the Company or any Subsidiary and, to the knowledge of the Company, none of the employees of the Company or any Subsidiary is presently a party to any transaction with the Company or any Subsidiary (other than for services as employees, officers and directors), including any contract, agreement or other arrangement providing for the furnishing of services to or by, providing for rental of real or personal property to or from, providing for the borrowing of money from or lending of money to or otherwise requiring payments to or from any officer, director or such employee or, to the knowledge of the Company, any entity in which any officer, director, or any such employee has a substantial interest or is an officer, director, trustee, stockholder, member or partner, in each case in excess of $120,000 other than for (i) payment of salary or consulting or director fees for services rendered, (ii) reimbursement for expenses incurred on behalf of the Company, (iii) indemnification and advancement of expenses in connection with Actions that are disclosed in the SEC Reports, and (iv) other employee benefits, including equity awards, stock option agreements and restricted stock awards under any equity incentive plan or stock option plan of the Company.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">(s)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Sarbanes-Oxley; Internal Accounting Controls</u>. The Company and the Subsidiaries are in compliance in all material respects with any and all applicable requirements of the Sarbanes-Oxley Act of 2002, as amended, that are effective as of the date hereof, and any and all applicable rules and regulations promulgated by the Commission thereunder that are effective as of the date hereof. Except as set forth in the SEC Reports, the Company and the Subsidiaries maintain a system of internal accounting controls sufficient to provide reasonable assurance that: (i) transactions are executed in accordance with management&#8217;s general or specific authorizations, (ii) transactions are recorded as necessary to permit preparation of financial statements in conformity with GAAP and to maintain asset accountability, (iii) access to assets is permitted only in accordance with management&#8217;s general or specific authorization, and (iv) the recorded accountability for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences. Except as set forth in the SEC Reports, the Company and the Subsidiaries have established disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the Company and the Subsidiaries and designed such disclosure controls and procedures to ensure that information required to be disclosed by the Company in the reports it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Commission&#8217;s rules and forms. The Company&#8217;s certifying officers have evaluated the effectiveness of the disclosure controls and procedures of the Company and the Subsidiaries as of the end of the period covered by the most recently filed periodic report under the Exchange Act (such date, the &#8220;<u>Evaluation Date</u>&#8221;). The Company presented in its most recently filed periodic report under the Exchange Act the conclusions of the certifying officers about the effectiveness of the disclosure controls and procedures based on their evaluations as of the Evaluation Date. Since the Evaluation Date, there have been no changes in the internal control over financial reporting (as such term is defined in the Exchange Act) of the Company and its Subsidiaries that have materially affected, or is reasonably likely to materially affect, the internal control over financial reporting of the Company and its Subsidiaries.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="15" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">15</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">(t)&nbsp;&nbsp; &nbsp; &nbsp; <u>Certain Fees</u>. Except for fees payable by the Company to the Placement Agent, no brokerage or finder&#8217;s fees or commissions are or will be payable by the Company or any Subsidiary to any broker, financial advisor or consultant, finder, placement agent, investment banker, bank or other Person with respect to the transactions contemplated by the Transaction Documents. The Purchasers shall have no obligation with respect to any fees or with respect to any claims made by or on behalf of other Persons for fees of a type contemplated in this Section that may be due in connection with the transactions contemplated by the Transaction Documents.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">(u)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Investment Company</u>. The Company is not, and is not an Affiliate of, and immediately after receipt of payment for the Securities, will not be or be an Affiliate of, an &#8220;investment company&#8221; within the meaning of the Investment Company Act of 1940, as amended. The Company shall conduct its business in a manner so that it will not become an &#8220;investment company&#8221; subject to registration under the Investment Company Act of 1940, as amended.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">(v)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Registration Rights</u>. Other than as set forth in the SEC Reports, no Person has any right to cause the Company or any Subsidiary to effect the registration under the Securities Act of any securities of the Company or any Subsidiary.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">(w)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Listing and Maintenance Requirements</u>. The Common Stock is registered pursuant to Section 12(b) or 12(g) of the Exchange Act, and the Company has taken no action designed to, or which to its knowledge is likely to have the effect of, terminating the registration of the Common Stock under the Exchange Act nor has the Company received any notification that the Commission is contemplating terminating such registration. Except as set forth in the SEC Reports, the Company has not, in the 12 months preceding the date hereof, received notice from any Trading Market on which the Common Stock is or has been listed or quoted to the effect that the Company is not in compliance with the listing or maintenance requirements of such Trading Market. Except as set forth in the SEC Reports, the Company is, and has no reason to believe that it will not in the foreseeable future continue to be, in compliance with all such listing and maintenance requirements. The Common Stock is currently eligible for electronic transfer through the Depository Trust Company or another established clearing corporation and the Company is current in payment of the fees to the Depository Trust Company (or such other established clearing corporation) in connection with such electronic transfer.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="16" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">16</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">(x)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Application of Takeover Protections</u>. The Company and the Board of Directors have taken all necessary action, if any, in order to render inapplicable any control share acquisition, business combination, poison pill (including any distribution under a rights agreement) or other similar anti&#8209;takeover provision under the Company&#8217;s certificate of incorporation (or similar charter documents) or the laws of its state of incorporation that is or could become applicable to the Purchasers as a result of the Purchasers and the Company fulfilling their obligations or exercising their rights under the Transaction Documents, including without limitation as a result of the Company&#8217;s issuance of the Securities and the Purchasers&#8217; ownership of the Securities.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">(y)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Disclosure</u>. Except with respect to the material terms and conditions of the transactions contemplated by the Transaction Documents, the Company confirms that neither it nor any other authorized Person acting on its behalf has provided any of the Purchasers or their agents or counsel with any information that it believes constitutes or might constitute material, non-public information which is not otherwise disclosed in the Prospectus Supplement. The Company understands and confirms that the Purchasers will rely on the foregoing representation in effecting transactions in securities of the Company. All of the disclosure furnished by or on behalf of the Company to the Purchasers regarding the Company and its Subsidiaries, their respective businesses and the transactions contemplated hereby is true and correct in all material respects as of the date made and does not contain any untrue statement of a material fact or omit to state any material fact necessary in order to make the statements made therein, in the light of the circumstances under which they were made, not misleading. The Company acknowledges and agrees that no Purchaser makes or has made any representations or warranties with respect to the transactions contemplated hereby other than those specifically set forth in Section 3.2 hereof.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">(z)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>No Integrated Offering</u>. Assuming the accuracy of the Purchasers&#8217; representations and warranties set forth in Section 3.2, neither the Company, nor any of its Affiliates, nor any Person acting on its or their behalf has knowingly, directly or indirectly, made any offers or sales of any security or solicited any offers to buy any security, under circumstances that would cause this offering of the Securities to be integrated with prior offerings by the Company for purposes of any applicable shareholder approval provisions of any Trading Market on which any of the securities of the Company are listed or designated.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">(aa)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Disclosure of Indebtedness in SEC Reports</u>. The SEC Reports set forth, as of the date of the respective quarter or year-end or other applicable date, as applicable, set forth in such SEC Report, all outstanding secured and unsecured Indebtedness of the Company or any Subsidiary, or for which the Company or any Subsidiary has commitments. For the purposes of this Agreement, &#8220;<u>Indebtedness</u>&#8221; means (x) any liabilities for borrowed money or amounts owed in excess of $50,000 (other than trade accounts payable incurred in the ordinary course of business), (y) all guaranties, endorsements and other contingent obligations in respect of indebtedness of others, whether or not the same are or should be reflected in the Company&#8217;s consolidated balance sheet (or the notes thereto), except guaranties by endorsement of negotiable instruments for deposit or collection or similar transactions in the ordinary course of business; and (z) the present value of any lease payments in excess of $50,000 due under leases required to be capitalized in accordance with GAAP. Neither the Company nor any Subsidiary is in default with respect to any Indebtedness.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="17" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">17</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">(bb)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Tax Status</u>. Except for matters that would not, individually or in the aggregate, have or reasonably be expected to result in a Material Adverse Effect, the Company and its Subsidiaries each (i) has made or filed all United States federal, state and local income and all foreign income and franchise tax returns, reports and declarations required by any jurisdiction to which it is subject, (ii) has paid all taxes and other governmental assessments and charges that are material in amount, shown or determined to be due on such returns, reports and declarations and (iii) has set aside on its books provision reasonably adequate for the payment of all material taxes for periods subsequent to the periods to which such returns, reports or declarations apply. There are no unpaid taxes in any material amount claimed to be due by the taxing authority of any jurisdiction, and the officers of the Company or of any Subsidiary know of no basis for any such claim.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">(cc)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Foreign Corrupt Practices</u>. Neither the Company nor any Subsidiary, nor to the knowledge of the Company or any Subsidiary, any agent or other person acting on behalf of the Company or any Subsidiary, has (i) directly or indirectly, used any funds for unlawful contributions, gifts, entertainment or other unlawful expenses related to foreign or domestic political activity, (ii) made any unlawful payment to foreign or domestic government officials or employees or to any foreign or domestic political parties or campaigns from corporate funds, (iii) failed to disclose fully any contribution made by the Company or any Subsidiary (or made by any person acting on its behalf of which the Company is aware) which is in violation of law, or (iv) violated in any material respect any provision of FCPA.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">(dd)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Accountants</u>. The Company&#8217;s accounting firm is set forth in the SEC Reports. To the knowledge and belief of the Company, such accounting firm (i) is a registered public accounting firm as required by the Exchange Act and (ii) shall express its opinion with respect to the financial statements to be included in the Company&#8217;s Annual Report for the fiscal year ending December 31, 2023.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">(ee)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Acknowledgment Regarding Purchasers</u><u>&#8217;</u><u> Purchase of Securities</u>. The Company acknowledges and agrees that each of the Purchasers is acting solely in the capacity of an arm&#8217;s length purchaser with respect to the Transaction Documents and the transactions contemplated thereby. The Company further acknowledges that no Purchaser is acting as a financial advisor or fiduciary of the Company (or in any similar capacity) with respect to the Transaction Documents and the transactions contemplated thereby and any advice given by any Purchaser or any of their respective representatives or agents in connection with the Transaction Documents and the transactions contemplated thereby is merely incidental to the Purchasers&#8217; purchase of the Securities. The Company further represents to each Purchaser that the Company&#8217;s decision to enter into this Agreement and the other Transaction Documents has been based solely on the independent evaluation of the transactions contemplated hereby by the Company and its representatives.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="18" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">18</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">(ff)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Acknowledgment Regarding Purchaser</u><u>&#8217;</u><u>s Trading Activity</u>. Anything in this Agreement or elsewhere herein to the contrary notwithstanding (except for Sections 3.2(f) and 4.13 hereof), it is understood and acknowledged by the Company that: (i) none of the Purchasers has been asked by the Company to agree, nor has any Purchaser agreed, to desist from purchasing or selling, long and/or short, securities of the Company, or &#8220;derivative&#8221; securities based on securities issued by the Company or to hold the Securities for any specified term; (ii) past or future open market or other transactions by any Purchaser, specifically including, without limitation, Short Sales or &#8220;derivative&#8221; transactions, before or after the closing of this or future private placement transactions, may negatively impact the market price of the Company&#8217;s publicly-traded securities; (iii) any Purchaser, and counter-parties in &#8220;derivative&#8221; transactions to which any such Purchaser is a party, directly or indirectly, presently may have a &#8220;short&#8221; position in the Common Stock, and (iv) each Purchaser shall not be deemed to have any affiliation with or control over any arm&#8217;s length counter-party in any &#8220;derivative&#8221; transaction. The Company further understands and acknowledges that (y) one or more Purchasers may engage in hedging activities at various times during the period that the Securities are outstanding, and (z) such hedging activities (if any) could reduce the value of the existing stockholders' equity interests in the Company at and after the time that the hedging activities are being conducted.&nbsp; The Company acknowledges that such aforementioned hedging activities do not constitute a breach of any of the Transaction Documents.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">(gg)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Regulation M Compliance</u>.&nbsp; The Company has not, and to its knowledge no one acting on its behalf has, (i) taken, directly or indirectly, any action designed to cause or to result in the stabilization or manipulation of the price of any security of the Company to facilitate the sale or resale of any of the Securities, (ii) sold, bid for, purchased, or, paid any compensation for soliciting purchases of, any of the Securities, or (iii) paid or agreed to pay to any Person any compensation for soliciting another to purchase any other securities of the Company, other than, in the case of clauses (ii) and (iii), compensation paid to the Placement Agent in connection with the placement of the Securities.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">(hh)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>FDA</u>. Except as disclosed in the SEC Reports, each product subject to the jurisdiction of the U.S. Food and Drug Administration (&#8220;<u>FDA</u>&#8221;) under the Federal Food, Drug and Cosmetic Act, as amended, and the regulations thereunder (&#8220;<u>FDCA</u>&#8221;) that is manufactured, packaged, labeled, tested, distributed, sold, and/or marketed by the Company or any of its Subsidiaries (each such product, a &#8220;<u>Pharmaceutical Product</u>&#8221;), such Pharmaceutical Product is being manufactured, packaged, labeled, tested, distributed, sold and/or marketed by the Company in compliance with all applicable requirements under FDCA and similar laws, rules and regulations relating to registration, investigational use, premarket clearance, licensure, or application approval, good manufacturing practices, good laboratory practices, good clinical practices, product listing, quotas, labeling, advertising, record keeping and filing of reports, except where the failure to be in compliance would not have a Material Adverse Effect. Except as disclosed in the SEC Reports, there is no pending, completed or, to the Company's knowledge, threatened, action (including any lawsuit, arbitration, or legal or administrative or regulatory proceeding, charge, complaint, or investigation) against the Company or any of its Subsidiaries, and none of the Company or any of its Subsidiaries has received any notice, warning letter or other communication from the FDA or any other governmental entity, which (i) contests the premarket clearance, licensure, registration, or approval of, the uses of, the distribution of, the manufacturing or packaging of, the testing of, the sale of, or the labeling and promotion of any Pharmaceutical Product, (ii) withdraws its approval of, requests the recall, suspension, or seizure of, or withdraws or orders the withdrawal of advertising or sales promotional materials relating to, any Pharmaceutical Product, (iii) imposes a clinical hold on any clinical investigation by the Company or any of its Subsidiaries, (iv) enjoins production at any facility of the Company or any of its Subsidiaries, (v) enters or proposes to enter into a consent decree of permanent injunction with the Company or any of its Subsidiaries, or (vi) otherwise alleges any violation of any laws, rules or regulations by the Company or any of its Subsidiaries, and which, either individually or in the aggregate, would have a Material Adverse Effect. The properties, business and operations of the Company have been and are being conducted in all material respects in accordance with all applicable laws, rules and regulations of the FDA, except where the failure to be in compliance would not have a Material Adverse Effect.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="19" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">19</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Stock Option Plans</u>. Each stock option granted by the Company under the Company&#8217;s stock incentive plan was granted (i) in accordance with the terms of the Company&#8217;s stock incentive plan and (ii) with an exercise price at least equal to the fair market value of the Common Stock on the date such stock option would be considered granted under GAAP and applicable law. No stock option granted under the Company&#8217;s stock incentive plan has been backdated. The Company has not knowingly granted, and there is no and has been no Company policy or practice to knowingly grant, stock options prior to, or otherwise knowingly coordinate the grant of stock options with, the release or other public announcement of material information regarding the Company or its Subsidiaries or their financial results or prospects.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">(jj)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Cybersecurity</u>.&nbsp; (i)(x) To the Company&#8217;s knowledge, there has been no material security breach or other compromise of or relating to any of the Company&#8217;s or any Subsidiary&#8217;s information technology and computer systems, networks, hardware, software, data (including the data of its respective customers, employees, suppliers, vendors and any third party data maintained by or on behalf of it), equipment or technology (collectively, &#8220;<u>IT Systems and Data</u>&#8221;) and (y) the Company and the Subsidiaries have not been notified of any security breach or other compromise to its IT Systems and Data, in each case, except as would not, individually or in the aggregate, have a Material Adverse Effect; (ii) the Company and the Subsidiaries are presently in compliance with all applicable laws or statutes and all judgments, orders, rules and regulations of any court or arbitrator or governmental or regulatory authority, internal policies and contractual obligations relating to the privacy and security of IT Systems and Data and to the protection of such IT Systems and Data from unauthorized use, access, misappropriation or modification, except as would not, individually or in the aggregate, have a Material Adverse Effect; (iii)&nbsp;the Company and the Subsidiaries have implemented and maintained commercially reasonable safeguards to maintain and protect its material confidential information and the integrity, operation, redundancy and security of all IT Systems and Data, except where the failure to do so would not have a Material Adverse Effect; and (iv) the Company and the Subsidiaries have implemented commercially reasonable backup and disaster recovery technology consistent with industry standards in all material respects and practices.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="20" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">20</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">(kk)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Compliance with Data Privacy Laws</u>. (i)&nbsp;The Company and the Subsidiaries are, and at all times during the past three years were, in compliance with all applicable data privacy and security laws and regulations, including, as applicable, the European Union General Data Protection Regulation (&#8220;<u>GDPR</u>&#8221;) (EU 2016/679) (collectively, &#8220;<u>Privacy Laws</u>&#8221;); (ii)&nbsp;the Company and the Subsidiaries have in place, comply with, and take appropriate steps reasonably designed to ensure compliance with their policies and procedures relating to data privacy and security and the collection, storage, use, disclosure, handling and analysis of Personal Data (the &#8220;<u>Policies</u>&#8221;); (iii)&nbsp;the Company provides accurate notice of its applicable Policies to its customers, employees, third party vendors and representatives as required by Privacy Laws; and (iv)&nbsp;applicable Policies provide accurate and sufficient notice of the Company&#8217;s then-current privacy practices relating to its subject matter, and do not contain any material omissions of the Company&#8217;s then-current privacy practices, as required by Privacy Laws, except for, in each case, failure or noncompliance that would not result in a Material Adverse Effect.&nbsp;&#8220;<u>Personal Data</u>&#8221; means (i)&nbsp;a natural person&#8217;s name, street address, telephone number, email address, photograph, social security number, bank information, or customer or account number; (ii)&nbsp;any information which would qualify as &#8220;personally identifying information&#8221; under the Federal Trade Commission Act, as amended; (iii) &#8220;personal data&#8221; as defined by GDPR; and (iv)&nbsp;any other piece of information that allows the identification of such natural person, or his or her family, or permits the collection or analysis of any identifiable data related to an identified person&#8217;s health or sexual orientation. (i)&nbsp;None of such disclosures made or contained in any of the Policies have been inaccurate, misleading, or deceptive in violation of any Privacy Laws and (ii)&nbsp;the execution, delivery and performance of the Transaction Documents will not result in a breach of any Privacy Laws or Policies, except, in both cases, such as would not have a Material Adverse Effect.&nbsp; Neither the Company nor the Subsidiaries, (i)&nbsp;has received written notice of any actual or potential liability of the Company or the Subsidiaries under, or actual or potential violation by the Company or the Subsidiaries of, any of the Privacy Laws; (ii)&nbsp;is currently conducting or paying for, in whole or in part, any investigation, remediation or other corrective action pursuant to any regulatory request or demand pursuant to any Privacy Law; or (iii)&nbsp;is a party to any order, decree, or agreement by or with any court or arbitrator or governmental or regulatory authority that imposed any obligation or liability under any Privacy Law, except, in each case, such as would not have a Material Adverse Effect.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="21" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">21</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">(ll)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Office of Foreign Assets Control</u>. Neither the Company nor any of its Subsidiaries, nor to the knowledge of the Company, any of the directors, officers or employees of the Company or its Subsidiaries, is an individual or entity that is, or is owned or controlled by an individual or entity that is: (i)&nbsp;the subject of any sanctions administered or enforced by the U.S. Department of Treasury&#8217;s Office of Foreign Assets Control, the United Nations Security Council, the European Union, Her Majesty&#8217;s Treasury, or other relevant sanctions authority (collectively, &#8220;<u>Sanctions</u>&#8221;), nor (ii)&nbsp;located, organized or resident in a country or territory that is the subject of Sanctions. Neither the Company nor any of its Subsidiaries will, directly or indirectly, knowingly use the proceeds of the transactions contemplated hereby, or lend, contribute or otherwise make available such proceeds to any Subsidiary, joint venture partner or other individual or entity: (i)&nbsp;to fund or facilitate any activities or business of or with any individual or entity or in any country or territory that, at the time of such funding or facilitation, is the subject of Sanctions or (ii)&nbsp;in any other manner that will result in a violation of Sanctions by any individual or entity (including any individual or entity participating in the transactions contemplated hereby, whether as underwriter, advisor, investor or otherwise). For the past five years, neither the Company nor any of its Subsidiaries has knowingly engaged in, and is not now knowingly engaged in, any dealings or transactions with any individual or entity, or in any country or territory, that at the time of the dealing or transaction is or was the subject of Sanctions.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">(mm)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Money Laundering</u>. The operations of the Company and its Subsidiaries are and have been conducted at all times in compliance with applicable financial record-keeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended, applicable money laundering statutes and applicable rules and regulations thereunder (collectively, the &#8220;<u>Money Laundering Laws</u>&#8221;), and no Action or Proceeding by or before any court or governmental agency, authority or body or any arbitrator involving the Company or any Subsidiary with respect to the Money Laundering Laws is pending or, to the knowledge of the Company or any Subsidiary, threatened.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">3.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Representations and Warranties of the Purchasers</u>. Each Purchaser, for itself and for no other Purchaser, hereby represents and warrants as of the date hereof and as of the Closing Date to the Company as follows (unless as of a specific date therein, in which case they shall be accurate as of such date):</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 21pt; text-indent: 51pt; text-align: justify;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Organization; Authority</u>. Such Purchaser is either an individual or an entity duly incorporated or formed, validly existing and in good standing under the laws of the jurisdiction of its incorporation or formation with full right, corporate, partnership limited liability company or similar power and authority to enter into and to consummate the transactions contemplated by the Transaction Documents and otherwise to carry out its obligations hereunder and thereunder. The execution and delivery of the Transaction Documents and performance by such Purchaser of the transactions contemplated by the Transaction Documents have been duly authorized by all necessary corporate, partnership, limited liability company or similar action, as applicable, on the part of such Purchaser. Each Transaction Document to which it is a party has been duly executed by such Purchaser, and when delivered by such Purchaser in accordance with the terms hereof, will constitute the valid and legally binding obligation of such Purchaser, enforceable against it in accordance with its terms, except: (i) as limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application affecting enforcement of creditors&#8217; rights generally, (ii) as limited by laws relating to the availability of specific performance, injunctive relief or other equitable remedies and (iii) insofar as indemnification and contribution provisions may be limited by applicable law.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="22" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">22</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 21pt; text-indent: 51pt; text-align: justify;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Understandings or Arrangements</u>. Such Purchaser is acquiring the Securities as principal for its own account and has no direct or indirect arrangement or understandings with any other persons to distribute or regarding the distribution of such Securities (this representation and warranty not limiting such Purchaser&#8217;s right to sell the Securities pursuant to the Registration Statement or otherwise in compliance with applicable federal and state securities laws). Such Purchaser is acquiring the Securities hereunder in the ordinary course of its business.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 21pt; text-indent: 51pt; text-align: justify;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Purchaser Status</u>. At the time such Purchaser was offered the Securities, it was, and as of the date hereof it is, either (i) an &#8220;accredited investor&#8221; as defined in Rule 501(a)(1), (a)(2), (a)(3), (a)(7), (a)(8), (a)(9), (a)(12), or (a)(13) under the Securities Act or (ii) a &#8220;qualified institutional buyer&#8221; as defined in Rule 144A(a) under the Securities Act.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 21pt; text-indent: 51pt; text-align: justify;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Experience of Such Purchaser</u>. Such Purchaser, either alone or together with its representatives, has such knowledge, sophistication and experience in business and financial matters so as to be capable of evaluating the merits and risks of the prospective investment in the Securities, and has so evaluated the merits and risks of such investment. Such Purchaser is able to bear the economic risk of an investment in the Securities and, at the present time, is able to afford a complete loss of such investment.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 21pt; text-indent: 51pt; text-align: justify;">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Access to Information</u>. Such Purchaser acknowledges that it has had the opportunity to review the Transaction Documents (including all exhibits and schedules thereto) and the SEC Reports and has been afforded, (i) the opportunity to ask such questions as it has deemed necessary of, and to receive answers from, representatives of the Company concerning the terms and conditions of the offering of the Securities and the merits and risks of investing in the Securities; (ii) access to information about the Company and its financial condition, results of operations, business, properties, management and prospects sufficient to enable it to evaluate its investment; and (iii) the opportunity to obtain such additional information that the Company possesses or can acquire without unreasonable effort or expense that is necessary to make an informed investment decision with respect to the investment.&nbsp; Such Purchaser acknowledges and agrees that neither the Placement Agent nor any Affiliate of the Placement Agent has provided such Purchaser with any information or advice with respect to the Securities nor is such information or advice necessary or desired.&nbsp; Neither the Placement Agent nor any Affiliate has made or makes any representation as to the Company or the quality of the Securities and the Placement Agent and any Affiliate may have acquired non-public information with respect to the Company which such Purchaser agrees need not be provided to it.&nbsp; In connection with the issuance of the Securities to such Purchaser, neither the Placement Agent nor any of its Affiliates has acted as a financial advisor or fiduciary to such Purchaser.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="23" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">23</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 21pt; text-indent: 51pt; text-align: justify;">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Certain Transactions and Confidentiality</u>. Other than consummating the transactions contemplated hereunder, such Purchaser has not, nor has any Person acting on behalf of or pursuant to any understanding with such Purchaser, directly or indirectly executed any purchases or sales, including Short Sales,&nbsp;of the securities of the Company during the period commencing as of the time that such Purchaser first received a term sheet (written or oral) from the Company or any other Person representing the Company setting forth the material pricing terms of the transactions contemplated hereunder and ending immediately prior to the execution hereof. Notwithstanding the foregoing, in the case of a Purchaser that is a multi-managed investment vehicle whereby separate portfolio managers manage separate portions of such Purchaser&#8217;s assets and the portfolio managers have no direct knowledge of the investment decisions made by the portfolio managers managing other portions of such Purchaser&#8217;s assets, the representation set forth above shall only apply with respect to the portion of assets managed by the portfolio manager that made the investment decision to purchase the Securities covered by this Agreement. Other than to other Persons party to this Agreement or to such Purchaser&#8217;s representatives, including, without limitation, its officers, directors, partners, legal and other advisors, employees, agents and Affiliates, such Purchaser has maintained the confidentiality of all disclosures made to it in connection with this transaction (including the existence and terms of this transaction). Notwithstanding the foregoing, for the avoidance of doubt, nothing contained herein shall constitute a representation or warranty, or preclude any actions, with respect to locating or borrowing shares in order to effect Short Sales or similar transactions in the future.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company acknowledges and agrees that the representations contained in this Section 3.2 shall not modify, amend or affect such Purchaser&#8217;s right to rely on the Company&#8217;s representations and warranties contained in this Agreement or any representations and warranties contained in any other Transaction Document or any other document or instrument executed and/or delivered in connection with this Agreement or the consummation of the transactions contemplated hereby. Notwithstanding the foregoing, for the avoidance of doubt, nothing contained herein shall constitute a representation or warranty, or preclude any actions, with respect to locating or borrowing shares in order to effect Short Sales or similar transactions in the future.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b>ARTICLE IV.</b></p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">OTHER AGREEMENTS OF THE PARTIES</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:36pt;">4.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>[Intentionally omitted]</u></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">4.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Furnishing of Information</u>. Until the time that no Purchaser owns Securities, the Company covenants to timely file (or obtain extensions in respect thereof and file within the applicable grace period) all reports required to be filed by the Company after the date hereof pursuant to the Exchange Act even if the Company is not then subject to the reporting requirements of the Exchange Act.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">4.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Integration</u>. The Company shall not sell, offer for sale or solicit offers to buy or otherwise negotiate in respect of any security (as defined in Section 2 of the Securities Act) that would be integrated with the offer or sale of the Securities for purposes of the rules and regulations of any Trading Market such that it would require shareholder approval prior to the closing of such other transaction unless shareholder approval is obtained before the closing of such subsequent transaction.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="24" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">24</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">4.4&nbsp;&nbsp;&nbsp;&nbsp;<u>Securities Laws Disclosure; Publicity</u>. The Company shall (a) by the Disclosure Time, issue a press release disclosing the material terms of the transactions contemplated hereby, and (b) file a Current Report on Form 8-K, including the Transaction Documents as exhibits thereto, with the Commission within the time required by the Exchange Act. From and after the issuance of such press release, the Company represents to the Purchasers that it shall have publicly disclosed all material, non-public information delivered to any of the Purchasers by the Company or any of its Subsidiaries, or any of their respective officers, directors, employees, Affiliates or agents, including, without limitation, the Placement Agent, in connection with the transactions contemplated by the Transaction Documents. In addition, effective upon the issuance of such press release, the Company acknowledges and agrees that any and all confidentiality or similar obligations under any agreement, whether written or oral, between the Company, any of its Subsidiaries or any of their respective officers, directors, agents, employees, Affiliates or agents, including without limitation, the Placement Agent, on the one hand, and any of the Purchasers or any of their Affiliates on the other hand, shall terminate and be of no further force or effect. The Company understands and confirms that each Purchaser shall be relying on the foregoing covenant in effecting transactions in securities of the Company. The Company and each Purchaser shall consult with each other in issuing any other press releases with respect to the transactions contemplated hereby, and neither the Company nor any Purchaser shall issue any such press release nor otherwise make any such public statement without the prior consent of the Company, with respect to any press release of any Purchaser, or without the prior consent of each Purchaser, with respect to any press release of the Company, which consent shall not unreasonably be withheld or delayed, except if such disclosure is required by law, in which case the disclosing party shall promptly provide the other party with prior notice of such public statement or communication. Notwithstanding the foregoing, the Company shall not publicly disclose the name of any Purchaser, or include the name of any Purchaser in any filing with the Commission or any regulatory agency or Trading Market, without the prior written consent of such Purchaser, except (a) as required by federal securities law in connection with the filing of final Transaction Documents with the Commission and (b) to the extent such disclosure is required by law or Trading Market regulations, in which case the Company shall provide the Purchasers with prior notice of such disclosure permitted under this clause (b) and reasonably cooperate with such Purchaser regarding such disclosure.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">4.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Shareholder Rights Plan</u>. No claim will be made or enforced by the Company or, with the consent of the Company, any other Person, that any Purchaser is an &#8220;<u>Acquiring Person</u>&#8221; under any control share acquisition, business combination, poison pill (including any distribution under a rights agreement) or similar anti-takeover plan or arrangement in effect or hereafter adopted by the Company, or that any Purchaser could be deemed to trigger the provisions of any such plan or arrangement, by virtue of receiving Securities under the Transaction Documents or under any other agreement between the Company and the Purchasers.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">4.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Non-Public Information</u>. Except with respect to the material terms and conditions of the transactions contemplated by the Transaction Documents, which shall be disclosed pursuant to Section 4.4, the Company covenants and agrees that neither it, nor any other Person acting on its behalf will provide any Purchaser or its agents or counsel with any information that constitutes, or the Company reasonably believes constitutes, material non-public information, unless prior thereto such Purchaser shall have consented in writing to the receipt of such information and agreed in writing with the Company to keep such information confidential. The Company understands and confirms that each Purchaser shall be relying on the foregoing covenant in effecting transactions in securities of the Company. To the extent that the Company, any of its Subsidiaries, or any of their respective officers, directors, agents, employees or Affiliates delivers any material, non-public information to a Purchaser without such Purchaser&#8217;s consent, the Company hereby covenants and agrees that such Purchaser shall not have any duty of confidentiality to the Company, any of its Subsidiaries, or any of their respective officers, directors, employees, Affiliates or agents, including, without limitation, the Placement Agent, or a duty to the Company, any of its Subsidiaries or any of their respective officers, directors, employees, Affiliates or agents including, without limitation, the Placement Agent, not to trade on the basis of, such material, non-public information, provided that the Purchaser shall remain subject to applicable law. To the extent that any notice provided pursuant to any Transaction Document constitutes, or contains, material, non-public information regarding the Company or any Subsidiaries, the Company shall simultaneously with the delivery of such notice file such notice with the Commission pursuant to a Current Report on Form 8-K. The Company understands and confirms that each Purchaser shall be relying on the foregoing covenant in effecting transactions in securities of the Company.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="25" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">25</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">4.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Use of Proceeds</u>. Except as set forth in the Prospectus Supplement, the Company shall use the net proceeds from the sale of the Securities hereunder for working capital purposes and shall not use such proceeds: (a) for the satisfaction of any portion of the Company&#8217;s debt (other than payment of trade payables in the ordinary course of the Company&#8217;s business and prior practices), (b) for the redemption of any Common Stock or Common Stock Equivalents, (c) for the settlement of any outstanding litigation or (d) in violation of FCPA or OFAC regulations.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">4.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Indemnification of Purchasers</u>. Subject to the provisions of this Section 4.8, the Company will indemnify and hold each Purchaser and its directors, officers, shareholders, members, partners, employees and agents (and any other Persons with a functionally equivalent role of a Person holding such titles notwithstanding a lack of such title or any other title), each Person who controls such Purchaser (within the meaning of Section 15 of the Securities Act and Section 20 of the Exchange Act), and the directors, officers, shareholders, agents, members, partners or employees (and any other Persons with a functionally equivalent role of a Person holding such titles notwithstanding a lack of such title or any other title) of such controlling persons (each, a &#8220;Purchaser Party&#8221;) harmless from any and all losses, liabilities, obligations, claims, contingencies, damages, costs and expenses, including all judgments, amounts paid in settlements, court costs and reasonable attorneys&#8217; fees and costs of investigation that any such Purchaser Party may suffer or incur as a result of or relating to (a) any breach of any of the representations, warranties, covenants or agreements made by the Company in this Agreement or in the other Transaction Documents or (b) any action instituted against the Purchaser Parties in any capacity, or any of them or their respective Affiliates, by any stockholder of the Company who is not an Affiliate of such Purchaser Party, with respect to any of the transactions contemplated by the Transaction Documents (unless such action is solely based upon a material breach of such Purchaser Party&#8217;s representations, warranties or covenants under the Transaction Documents or any agreements or understandings such Purchaser Party may have with any such stockholder or any violations by such Purchaser Party of state or federal securities laws or any conduct by such Purchaser Party which is finally judicially determined to constitute fraud, gross negligence or willful misconduct. If any action shall be brought against any Purchaser Party in respect of which indemnity may be sought pursuant to this Agreement, such Purchaser Party shall promptly notify the Company in writing, and, the Company shall have the right to assume the defense thereof with counsel of its own choosing reasonably acceptable to the Purchaser Party. Any Purchaser Party shall have the right to employ separate counsel in any such action and participate in the defense thereof, but the fees and expenses of such counsel shall be at the expense of such Purchaser Party except to the extent that (i) the employment thereof has been specifically authorized by the Company in writing, (ii) the Company has failed after a reasonable period of time to assume such defense and to employ counsel or (iii) in such action there is, in the reasonable opinion of counsel a material conflict on any material issue between the position of the Company and the position of such Purchaser Party, in which case the Company shall be responsible for the reasonable fees and expenses of no more than one such separate counsel. The Company will not be liable to any Purchaser Party under this Agreement (y) for any settlement by a Purchaser Party effected without the Company&#8217;s prior written consent, which shall not be unreasonably withheld or delayed; or (z) to the extent, but only to the extent that a loss, claim, damage or liability is attributable to any Purchaser Party&#8217;s breach of any of the representations<u>, warranties, covenants or agreements</u> made by such Purchaser Party in this Agreement <u>or in the other Transaction Documents</u>. The indemnification required by this Section 4.8 shall be made by periodic payments of the amount thereof during the course of the investigation or defense, as and when bills are received or are incurred. The indemnity agreements contained herein shall be in addition to any cause of action or similar right of any Purchaser Party against the Company or others and any liabilities the Company may be subject to pursuant to law.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="26" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">26</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">4.9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Reservation of Common Stock</u>. As of the date hereof, the Company has reserved and the Company shall continue to reserve and keep available at all times, free of preemptive rights, a sufficient number of shares of Common Stock for the purpose of enabling the Company to issue Shares pursuant to this Agreement.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">4.10&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Listing of Common Stock</u>. The Company hereby agrees to use best efforts to maintain the listing or quotation of the Common Stock on the Trading Market on which it is currently listed, and concurrently with the Closing, the Company shall apply to list or quote all of the Shares on such Trading Market and promptly secure the listing of all of the Shares on such Trading Market. The Company further agrees, if the Company applies to have the Common Stock traded on any other Trading Market, it will then include in such application all of the Shares, and will take such other action as is necessary to cause all of the Shares to be listed or quoted on such other Trading Market as promptly as possible. The Company will then take all action reasonably necessary to continue the listing and trading of its Common Stock on a Trading Market and will comply in all respects with the Company&#8217;s reporting, filing and other obligations under the bylaws or rules of the Trading Market. The Company agrees to maintain the eligibility of the Common Stock for electronic transfer through the Depository Trust Company or another established clearing corporation, including, without limitation, by timely payment of fees to the Depository Trust Company or such other established clearing corporation in connection with such electronic transfer.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:36pt;">4.11&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Subsequent Equity Sales</u>.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">(a)&nbsp;&nbsp;&nbsp;&nbsp;From the date hereof until 30 days after the Closing Date, neither the Company nor any Subsidiary shall (i) issue, enter into any agreement to issue or announce the issuance or proposed issuance of any shares of Common Stock or Common Stock Equivalents or (ii) file any registration statement or amendment or supplement thereto, other than the Prospectus Supplement or filing a registration statement on Form S-8 in connection with any employee benefit plan.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="27" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">27</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">(b)&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding the foregoing, this Section 4.11 shall not apply in respect of an Exempt Issuance.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">4.12&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Equal Treatment of Purchasers</u>. No consideration (including any modification of this Agreement) shall be offered or paid to any Person to amend or consent to a waiver or modification of any provision of this Agreement unless the same consideration is also offered to all of the parties to this Agreement. For clarification purposes, this provision constitutes a separate right granted to each Purchaser by the Company and negotiated separately by each Purchaser, and is intended for the Company to treat the Purchasers as a class and shall not in any way be construed as the Purchasers acting in concert or as a group with respect to the purchase, disposition or voting of Securities or otherwise.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">4.13&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Certain Transactions and Confidentiality</u>. Each Purchaser, severally and not jointly with the other Purchasers, covenants that neither it nor any Affiliate acting on its behalf or pursuant to any understanding with it will execute any purchases or sales, including Short Sales of any of the Company&#8217;s securities during the period commencing with the execution of this Agreement and ending at such time that the transactions contemplated by this Agreement are first publicly announced pursuant to the initial press release as described in Section 4.4.&nbsp; Each Purchaser, severally and not jointly with the other Purchasers, covenants that until such time as the transactions contemplated by this Agreement are publicly disclosed by the Company pursuant to the initial press release as described in Section 4.4, such Purchaser will maintain the confidentiality of the existence and terms of this transaction (other than as disclosed to its legal and other representatives).&nbsp; Notwithstanding the foregoing, and notwithstanding anything contained in this Agreement to the contrary, the Company expressly acknowledges and agrees that (i) no Purchaser makes any representation, warranty or covenant hereby that it will not engage in effecting transactions in any securities of the Company after the time that the transactions contemplated by this Agreement are first publicly announced pursuant to the initial press release as described in Section 4.4, (ii) no Purchaser shall be restricted or prohibited from effecting any transactions in any securities of the Company in accordance with applicable securities laws from and after the time that the transactions contemplated by this Agreement are first publicly announced pursuant to the initial press release as described in Section 4.4 and (iii) no Purchaser shall have any duty of confidentiality or duty not to trade in the securities of the Company to the Company, any of its Subsidiaries, or any of their respective officers, directors, employees, Affiliates or agent, including without limitation, the Placement Agent, after the issuance of the initial press release as described in Section 4.4.&nbsp; Notwithstanding the foregoing, in the case of a Purchaser that is a multi-managed investment vehicle whereby separate portfolio managers manage separate portions of such Purchaser&#8217;s assets and the portfolio managers have no direct knowledge of the investment decisions made by the portfolio managers managing other portions of such Purchaser&#8217;s assets, the covenant set forth above shall only apply with respect to the portion of assets managed by the portfolio manager that made the investment decision to purchase the Securities covered by this Agreement.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">4.14&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>[Intentionally omitted]</u></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="28" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">28</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b>ARTICLE V.</b></p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">MISCELLANEOUS</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">5.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Termination</u>.&nbsp; This Agreement may be terminated by any Purchaser, as to such Purchaser&#8217;s obligations hereunder only and without any effect whatsoever on the obligations between the Company and the other Purchasers, by written notice to the other parties, if the Closing has not been consummated on or before the fifth (5<sup style="vertical-align:top;line-height:120%;">th</sup>) Trading Day following the date hereof; <u>provided</u>, <u>however</u>, that no such termination will affect the right of any party to sue for any breach by any other party (or parties).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">5.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Fees and Expenses</u>. Except as expressly set forth in the Transaction Documents to the contrary, each party shall pay the fees and expenses of its advisers, counsel, accountants and other experts, if any, and all other expenses incurred by such party incident to the negotiation, preparation, execution, delivery and performance of this Agreement. The Company shall pay all Transfer Agent fees (including, without limitation, any fees required for same-day processing of any instruction letter delivered by the Company), stamp taxes and other taxes and duties levied in connection with the delivery of any Securities to the Purchasers.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">5.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Entire Agreement</u>. The Transaction Documents, together with the exhibits and schedules thereto, the Prospectus and the Prospectus Supplement, contain the entire understanding of the parties with respect to the subject matter hereof and thereof and supersede all prior agreements and understandings, oral or written, with respect to such matters, which the parties acknowledge have been merged into such documents, exhibits and schedules.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">5.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Notices</u>. Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall be in writing and shall be deemed given and effective on the earliest of: (a) the time of transmission, if such notice or communication is delivered via email attachment at the email address as set forth on the signature pages attached hereto at or prior to 5:30 p.m. (New York City time) on a Trading Day, (b) the next Trading Day after the time of transmission, if such notice or communication is delivered via email attachment at the email address as set forth on the signature pages attached hereto on a day that is not a Trading Day or later than 5:30 p.m. (New York City time) on any Trading Day, (c) the second (2<sup style="vertical-align:top;line-height:120%;">nd</sup>) Trading Day following the date of mailing, if sent by U.S. nationally recognized overnight courier service or (d) upon actual receipt by the party to whom such notice is required to be given. The address for such notices and communications shall be as set forth on the signature pages attached hereto.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">5.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Amendments; Waivers</u>. No provision of this Agreement may be waived, modified, supplemented or amended except in a written instrument signed, in the case of an amendment, by the Company and Purchasers which purchased at least 50.1% in interest of the Shares based on the initial Subscription Amounts hereunder (or, prior to the Closing, the Company and each Purchaser) or, in the case of a waiver, by the party against whom enforcement of any such waived provision is sought, provided that if any amendment, modification or waiver disproportionately and adversely impacts a Purchaser (or group of Purchasers), the consent of such disproportionately impacted Purchaser (or group of Purchasers) shall also be required. No waiver of any default with respect to any provision, condition or requirement of this Agreement shall be deemed to be a continuing waiver in the future or a waiver of any subsequent default or a waiver of any other provision, condition or requirement hereof, nor shall any delay or omission of any party to exercise any right hereunder in any manner impair the exercise of any such right. Any proposed amendment or waiver that disproportionately, materially and adversely affects the rights and obligations of any Purchaser relative to the comparable rights and obligations of the other Purchasers shall require the prior written consent of such adversely affected Purchaser. Any amendment effected in accordance with this Section 5.5 shall be binding upon each Purchaser and holder of Securities and the Company.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="29" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">29</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">5.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Headings</u>. The headings herein are for convenience only, do not constitute a part of this Agreement and shall not be deemed to limit or affect any of the provisions hereof.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">5.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Successors and Assigns</u>. This Agreement shall be binding upon and inure to the benefit of the parties and their successors and permitted assigns. The Company may not assign this Agreement or any rights or obligations hereunder without the prior written consent of each Purchaser (other than by merger). Any Purchaser may assign any or all of its rights under this Agreement to any Person to whom such Purchaser assigns or transfers any Securities, provided that such transferee agrees in writing to be bound, with respect to the transferred Securities, by the provisions of the Transaction Documents that apply to the &#8220;Purchasers.&#8221;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">5.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>No Third-Party Beneficiaries</u>. The Placement Agent shall be the third party beneficiary of the representations, warranties, and covenants of the Company in this Agreement and the representations, warranties, and covenants of the Purchasers in this Agreement. This Agreement is intended for the benefit of the parties hereto and their respective successors and permitted assigns and is not for the benefit of, nor may any provision hereof be enforced by, any other Person, except as otherwise set forth in Section 4.8 and this Section 5.8.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">5.9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Governing Law</u>. All questions concerning the construction, validity, enforcement and interpretation of the Transaction Documents shall be governed by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the principles of conflicts of law thereof. Each party agrees that all legal Proceedings concerning the interpretations, enforcement and defense of the transactions contemplated by this Agreement and any other Transaction Documents (whether brought against a party hereto or its respective affiliates, directors, officers, shareholders, partners, members, employees or agents) shall be commenced exclusively in the state and federal courts sitting in the City of New York. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in the City of New York, Borough of Manhattan for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein (including with respect to the enforcement of any of the Transaction Documents), and hereby irrevocably waives, and agrees not to assert in any Action or Proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such Action or Proceeding is improper or is an inconvenient venue for such Proceeding. Each party hereby irrevocably waives personal service of process and consents to process being served in any such Action or Proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under this Agreement and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any other manner permitted by law. If any party shall commence an Action or Proceeding to enforce any provisions of the Transaction Documents, then, in addition to the obligations of the Company under Section 4.8, the prevailing party in such Action or Proceeding shall be reimbursed by the non-prevailing party for its reasonable attorneys&#8217; fees and other costs and expenses incurred with the investigation, preparation and prosecution of such Action or Proceeding.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="30" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">30</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">5.10&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Survival</u>. The representations and warranties contained herein shall survive the Closing and the delivery of the Securities.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">5.11&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Execution</u>. This Agreement may be executed in two or more counterparts, all of which when taken together shall be considered one and the same agreement and shall become effective when counterparts have been signed by each party and delivered to each other party, it being understood that the parties need not sign the same counterpart. In the event that any signature is delivered by e-mail delivery of a &#8220;.pdf&#8221; format data file <u>or by any other electronic means</u>, such signature shall create a valid and binding obligation of the party executing (or on whose behalf such signature is executed) with the same force and effect as if such &#8220;.pdf&#8221; <u>or electronic </u>signature page were an original thereof.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">5.12&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Severability</u>. If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction to be invalid, illegal, void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein shall remain in full force and effect and shall in no way be affected, impaired or invalidated, and the parties hereto shall use their commercially reasonable efforts to find and employ an alternative means to achieve the same or substantially the same result as that contemplated by such term, provision, covenant or restriction. It is hereby stipulated and declared to be the intention of the parties that they would have executed the remaining terms, provisions, covenants and restrictions without including any of such that may be hereafter declared invalid, illegal, void or unenforceable.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">5.13&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Rescission and Withdrawal Right</u>. Notwithstanding anything to the contrary contained in (and without limiting any similar provisions of) any of the other Transaction Documents, whenever any Purchaser exercises a right, election, demand or option under a Transaction Document and the Company does not timely perform its related obligations within the periods therein provided, then such Purchaser may rescind or withdraw, in its sole discretion from time to time upon written notice to the Company, any relevant notice, demand or election in whole or in part without prejudice to its future actions and rights.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">5.14&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Replacement of Securities</u>. If any certificate or instrument evidencing any Securities is mutilated, lost, stolen or destroyed, the Company shall issue or cause to be issued in exchange and substitution for and upon cancellation thereof (in the case of mutilation), or in lieu of and substitution therefor, a new certificate or instrument, but only upon receipt of evidence reasonably satisfactory to the Company of such loss, theft or destruction. The applicant for a new certificate or instrument under such circumstances shall also pay any reasonable third-party costs (including customary indemnity) associated with the issuance of such replacement Securities.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="31" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">31</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">5.15&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Remedies</u>. In addition to being entitled to exercise all rights provided herein or granted by law, including recovery of damages, each of the Purchasers and the Company will be entitled to specific performance under the Transaction Documents. The parties agree that monetary damages may not be adequate compensation for any loss incurred by reason of any breach of obligations contained in the Transaction Documents and hereby agree to waive and not to assert in any Action for specific performance of any such obligation the defense that a remedy at law would be adequate.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">5.16&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Payment Set Aside</u>. To the extent that the Company makes a payment or payments to any Purchaser pursuant to any Transaction Document or a Purchaser enforces or exercises its rights thereunder, and such payment or payments or the proceeds of such enforcement or exercise or any part thereof are subsequently invalidated, declared to be fraudulent or preferential, set aside, recovered from, disgorged by or are required to be refunded, repaid or otherwise restored to the Company, a trustee, receiver or any other Person under any law (including, without limitation, any bankruptcy law, state or federal law, common law or equitable cause of action), then to the extent of any such restoration the obligation or part thereof originally intended to be satisfied shall be revived and continued in full force and effect as if such payment had not been made or such enforcement or setoff had not occurred.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">5.17&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Independent Nature of Purchasers</u><u>&#8217;</u><u> Obligations and Rights</u>. The obligations of each Purchaser under any Transaction Document are several and not joint with the obligations of any other Purchaser, and no Purchaser shall be responsible in any way for the performance or non-performance of the obligations of any other Purchaser under any Transaction Document. Nothing contained herein or in any other Transaction Document, and no action taken by any Purchaser pursuant hereto or thereto, shall be deemed to constitute the Purchasers as a partnership, an association, a joint venture or any other kind of entity, or create a presumption that the Purchasers are in any way acting in concert or as a group with respect to such obligations or the transactions contemplated by the Transaction Documents. Each Purchaser shall be entitled to independently protect and enforce its rights including, without limitation, the rights arising out of this Agreement or out of the other Transaction Documents, and it shall not be necessary for any other Purchaser to be joined as an additional party in any Proceeding for such purpose. Each Purchaser has been represented by its own separate legal counsel in its review and negotiation of the Transaction Documents. For reasons of administrative convenience only, each Purchaser and its respective counsel have chosen to communicate with the Company through EGS. EGS does not represent any of the Purchasers and only represents the Placement Agent. The Company has elected to provide all Purchasers with the same terms and Transaction Documents for the convenience of the Company and not because it was required or requested to do so by any of the Purchasers. It is expressly understood and agreed that each provision contained in this Agreement and in each other Transaction Document is between the Company and a Purchaser, solely, and not between the Company and the Purchasers collectively and not between and among the Purchasers.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">5.18&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Liquidated Damages</u>. The Company&#8217;s obligations to pay any partial liquidated damages or other amounts owing under the Transaction Documents is a continuing obligation of the Company and shall not terminate until all unpaid partial liquidated damages and other amounts have been paid notwithstanding the fact that the instrument or security pursuant to which such partial liquidated damages or other amounts are due and payable shall have been canceled.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="32" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">32</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">5.19&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Saturdays, Sundays, Holidays, etc.</u>If the last or appointed day for the taking of any action or the expiration of any right required or granted herein shall not be a Business Day, then such action may be taken or such right may be exercised on the next succeeding Business Day.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">5.20&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Construction</u>. The parties agree that each of them and/or their respective counsel have reviewed and had an opportunity to revise the Transaction Documents and, therefore, the normal rule of construction to the effect that any ambiguities are to be resolved against the drafting party shall not be employed in the interpretation of the Transaction Documents or any amendments thereto. In addition, each and every reference to share prices and shares of Common Stock in any Transaction Document shall be subject to adjustment for reverse and forward stock splits, stock dividends, stock combinations and other similar transactions of the Common Stock that occur after the date of this Agreement.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">5.21<b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>WAIVER OF JURY TRIAL</u></b><b>. </b><b><u>IN ANY ACTION, SUIT, OR PROCEEDING IN ANY JURISDICTION BROUGHT BY ANY PARTY AGAINST ANY OTHER PARTY, THE PARTIES EACH KNOWINGLY AND INTENTIONALLY, TO THE GREATEST EXTENT PERMITTED BY APPLICABLE LAW, HEREBY ABSOLUTELY, UNCONDITIONALLY, IRREVOCABLY AND EXPRESSLY WAIVES FOREVER TRIAL BY JURY. </u></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i>(Signature Pages Follow)</i></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" data-number="33" data-prefix="" data-suffix="" style="text-align: center; width: 100%; font-size: 10pt; font-family: Times New Roman;">33</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:45pt;">IN WITNESS WHEREOF, the parties hereto have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories as of the date first indicated above.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table cellpadding="0pt" cellspacing="0pt" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 100%; margin-left: 0pt; margin-right: 0pt;">

		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 40%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>BIOCARDIA, INC.</b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&nbsp;</p>
			</td>
			<td style="vertical-align: top; width: 60%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><u>Address for Notice:</u></p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 40%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">By:__________________________________________</p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Name:</p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Title:</p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">With a copy to (which shall not constitute notice):</p>
			</td>
			<td style="vertical-align: top; width: 60%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">E-Mail:</p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&nbsp;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">SIGNATURE PAGE FOR PURCHASER FOLLOWS]</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" data-number="34" data-prefix="" data-suffix="" style="text-align: center; width: 100%; font-size: 10pt; font-family: Times New Roman;">34</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">[PURCHASER SIGNATURE PAGES TO BCDA SECURITIES PURCHASE AGREEMENT]</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">IN WITNESS WHEREOF, the undersigned have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories as of the date first indicated above.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Name of Purchaser: ________________________________________________________</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Signature of Authorized Signatory of Purchaser</i>: _________________________________</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Name of Authorized Signatory: _______________________________________________</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Title of Authorized Signatory: ________________________________________________</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Email Address of Authorized Signatory:_________________________________________</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Address for Notice to Purchaser:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Subscription Amount: $_________________</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Shares: _________________</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">EIN Number: ____________________</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#9744; Notwithstanding anything contained in this Agreement to the contrary, by checking this box (i) the obligations of the above-signed to purchase the securities set forth in this Agreement to be purchased from the Company by the above-signed, and the obligations of the Company to sell such securities to the above-signed, shall be unconditional and all conditions to Closing shall be disregarded, (ii) the Closing shall occur on the second (2<sup style="vertical-align:top;line-height:120%;">nd</sup>) Trading Day following the date of this Agreement and (iii) any condition to Closing contemplated by this Agreement (but prior to being disregarded by clause (i) above) that required delivery by the Company or the above-signed of any agreement, instrument, certificate or the like or purchase price (as applicable) shall no longer be a condition and shall instead be an unconditional obligation of the Company or the above-signed (as applicable) to deliver such agreement, instrument, certificate or the like or purchase price (as applicable) to such other party on the Closing Date.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">[SIGNATURE PAGES CONTINUE]</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="35" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">35</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>bcda-20231116.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome Portal - 11/16/2023 8:26:19 PM-->
<xsd:schema xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:sic="http://xbrl.sec.gov/sic/2023" xmlns:currency="http://xbrl.sec.gov/currency/2023" xmlns:exch="http://xbrl.sec.gov/exch/2023" xmlns:bcda="http://www.bcda.com/20231116" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.bcda.com/20231116">
<xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
<xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/stpr/2023" schemaLocation="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd"/>
<xsd:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
<xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/country/2023" schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/sic/2023" schemaLocation="https://xbrl.sec.gov/sic/2023/sic-2023.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/currency/2023" schemaLocation="https://xbrl.sec.gov/currency/2023/currency-2023.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/exch/2023" schemaLocation="https://xbrl.sec.gov/exch/2023/exch-2023.xsd"/>

<xsd:annotation>
<xsd:appinfo>
<link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bcda-20231116_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
<link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bcda-20231116_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
<link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bcda-20231116_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
<link:roleType id="statement-document-and-entity-information" roleURI="http://www.bcda.com/20231116/role/statement-document-and-entity-information">
<link:definition xmlns="http://www.xbrl.org/2003/linkbase">000 - Document - Document And Entity Information</link:definition>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:presentationLink</link:usedOn>
</link:roleType>
</xsd:appinfo>
</xsd:annotation>
<xsd:element abstract="true" id="bcda_DocumentAndEntityInformation" name="DocumentAndEntityInformation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
<xsd:element abstract="true" id="bcda_CommonStockCustomMember" name="CommonStockCustomMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
<xsd:element abstract="true" id="bcda_WarrantToPurchaseCommonStockCustomMember" name="WarrantToPurchaseCommonStockCustomMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>5
<FILENAME>bcda-20231116_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome Portal - 11/16/2023 8:26:19 PM-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
<link:roleRef roleURI="http://www.bcda.com/20231116/role/statement-document-and-entity-information" xlink:href="bcda-20231116.xsd#statement-document-and-entity-information" xlink:type="simple"/>
<link:definitionLink xlink:role="http://www.bcda.com/20231116/role/statement-document-and-entity-information" xlink:type="extended">
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain-default" xlink:type="locator"/>
<link:loc xlink:href="bcda-20231116.xsd#bcda_CommonStockCustomMember" xlink:label="bcda_CommonStockCustomMember" xlink:type="locator"/>
<link:loc xlink:href="bcda-20231116.xsd#bcda_WarrantToPurchaseCommonStockCustomMember" xlink:label="bcda_WarrantToPurchaseCommonStockCustomMember" xlink:type="locator"/>
<link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
<link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
<link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" xlink:type="arc"/>
<link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain-default" xlink:type="arc"/>

<link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dei_DocumentInformationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
<link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dei_DocumentInformationTable" xlink:to="us-gaap_StatementClassOfStockAxis" xlink:type="arc"/>

<link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="bcda_CommonStockCustomMember" xlink:type="arc"/>
<link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="bcda_WarrantToPurchaseCommonStockCustomMember" xlink:type="arc"/>

<link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" xlink:type="arc"/>
<link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" xlink:type="arc"/>
<link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" xlink:type="arc"/>
<link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" xlink:type="arc"/>
<link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" xlink:type="arc"/>
<link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" xlink:type="arc"/>
<link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" xlink:type="arc"/>
<link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" xlink:type="arc"/>
<link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" xlink:type="arc"/>
<link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" xlink:type="arc"/>
<link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" xlink:type="arc"/>
<link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" xlink:type="arc"/>
<link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" xlink:type="arc"/>
<link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_WrittenCommunications" xlink:type="arc"/>
<link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SolicitingMaterial" xlink:type="arc"/>
<link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_PreCommencementTenderOffer" xlink:type="arc"/>
<link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_PreCommencementIssuerTenderOffer" xlink:type="arc"/>
<link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" xlink:type="arc"/>
<link:definitionArc order="18" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" xlink:type="arc"/>
<link:definitionArc order="19" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" xlink:type="arc"/>
<link:definitionArc order="20" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" xlink:type="arc"/>
<link:definitionArc order="21" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" xlink:type="arc"/>
<link:definitionArc order="22" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" xlink:type="arc"/>

</link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>bcda-20231116_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome Portal - 11/16/2023 8:26:19 PM-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple"/>
<link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
<link:label xlink:label="dei_EntityDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
<link:label xlink:label="dei_LegalEntityAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
<link:label xlink:label="dei_DocumentInformationLineItems-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Line Items]</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationLineItems-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
<link:label xlink:label="dei_DocumentInformationTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Table]</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationTable-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
<link:label xlink:label="dei_DocumentType-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document, Type</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
<link:label xlink:label="dei_DocumentPeriodEndDate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document, Period End Date</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
<link:label xlink:label="dei_EntityRegistrantName-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Registrant Name</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
<link:label xlink:label="dei_EntityIncorporationStateCountryCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Incorporation, State or Country Code</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xlink:type="locator"/>
<link:label xlink:label="dei_EntityFileNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, File Number</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
<link:label xlink:label="dei_EntityTaxIdentificationNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Tax Identification Number</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
<link:label xlink:label="dei_EntityAddressAddressLine1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Address, Address Line One</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
<link:label xlink:label="dei_EntityAddressCityOrTown-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Address, City or Town</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
<link:label xlink:label="dei_EntityAddressStateOrProvince-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Address, State or Province</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
<link:label xlink:label="dei_EntityAddressPostalZipCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Address, Postal Zip Code</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:type="locator"/>
<link:label xlink:label="dei_CityAreaCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:type="locator"/>
<link:label xlink:label="dei_LocalPhoneNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" xlink:type="locator"/>
<link:label xlink:label="dei_WrittenCommunications-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" xlink:type="locator"/>
<link:label xlink:label="dei_SolicitingMaterial-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" xlink:type="locator"/>
<link:label xlink:label="dei_PreCommencementTenderOffer-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" xlink:type="locator"/>
<link:label xlink:label="dei_PreCommencementIssuerTenderOffer-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:type="locator"/>
<link:label xlink:label="dei_Security12bTitle-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
<link:label xlink:label="dei_TradingSymbol-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xlink:type="locator"/>
<link:label xlink:label="dei_SecurityExchangeName-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
<link:label xlink:label="dei_EntityEmergingGrowthCompany-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Emerging Growth Company</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
<link:label xlink:label="dei_AmendmentFlag-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
<link:label xlink:label="dei_EntityCentralIndexKey-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Central Index Key</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:type="locator"/>
<link:label xlink:label="us-gaap_StatementClassOfStockAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xlink:type="locator"/>
<link:label xlink:label="us-gaap_ClassOfStockDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain-label" xlink:type="arc"/>

<link:loc xlink:href="bcda-20231116.xsd#bcda_CommonStockCustomMember" xlink:label="bcda_CommonStockCustomMember" xlink:type="locator"/>
<link:label xlink:label="bcda_CommonStockCustomMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">CommonStock Custom [Member]</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcda_CommonStockCustomMember" xlink:to="bcda_CommonStockCustomMember-label" xlink:type="arc"/>

<link:loc xlink:href="bcda-20231116.xsd#bcda_WarrantToPurchaseCommonStockCustomMember" xlink:label="bcda_WarrantToPurchaseCommonStockCustomMember" xlink:type="locator"/>
<link:label xlink:label="bcda_WarrantToPurchaseCommonStockCustomMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">WarrantToPurchaseCommonStock Custom [Member]</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcda_WarrantToPurchaseCommonStockCustomMember" xlink:to="bcda_WarrantToPurchaseCommonStockCustomMember-label" xlink:type="arc"/>


</link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>bcda-20231116_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome Portal - 11/16/2023 8:26:19 PM-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<link:roleRef roleURI="http://www.bcda.com/20231116/role/statement-document-and-entity-information" xlink:href="bcda-20231116.xsd#statement-document-and-entity-information" xlink:type="simple"/>
<link:presentationLink xlink:role="http://www.bcda.com/20231116/role/statement-document-and-entity-information" xlink:type="extended">
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xlink:type="locator"/>
<link:loc xlink:href="bcda-20231116.xsd#bcda_CommonStockCustomMember" xlink:label="bcda_CommonStockCustomMember" xlink:type="locator"/>
<link:loc xlink:href="bcda-20231116.xsd#bcda_WarrantToPurchaseCommonStockCustomMember" xlink:label="bcda_WarrantToPurchaseCommonStockCustomMember" xlink:type="locator"/>
<link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" xlink:type="arc"/>
<link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="bcda_CommonStockCustomMember" xlink:type="arc"/>
<link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="bcda_WarrantToPurchaseCommonStockCustomMember" xlink:type="arc"/>

<link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="us-gaap_StatementClassOfStockAxis" xlink:type="arc"/>

<link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationLineItems" xlink:type="arc"/>
<link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" xlink:type="arc"/>
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" xlink:type="arc"/>
<link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" xlink:type="arc"/>
<link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" xlink:type="arc"/>
<link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" xlink:type="arc"/>
<link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" xlink:type="arc"/>
<link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" xlink:type="arc"/>
<link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" xlink:type="arc"/>
<link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" xlink:type="arc"/>
<link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" xlink:type="arc"/>
<link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" xlink:type="arc"/>
<link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" xlink:type="arc"/>
<link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_WrittenCommunications" xlink:type="arc"/>
<link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SolicitingMaterial" xlink:type="arc"/>
<link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_PreCommencementTenderOffer" xlink:type="arc"/>
<link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_PreCommencementIssuerTenderOffer" xlink:type="arc"/>
<link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" xlink:type="arc"/>
<link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" xlink:type="arc"/>
<link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" xlink:type="arc"/>
<link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" xlink:type="arc"/>
<link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" xlink:type="arc"/>
<link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" xlink:type="arc"/>

</link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>image01.jpg
<TEXT>
begin 644 image01.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1"  [ (L# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]L_VJOVI?
M#G['OPFN/&GBJVUJXT6T=EN#IEI]IE@5899FD9=P^0)"V3GKCUJC^QG^V=X'
M_;Q^"L7CWX?W5[<Z&]Y-I[K>6_D7$$\1&Y'3)P<,C#GD.IKL/C3\)]*^.WPD
M\2^#=;B$FE>*-+NM)NOE!9([B%X7*^C;7;!K\;/^#>+]I(_L/^,OVF/A#\0)
MOL:_#ZVO/%4T1;:(Y-,+6^H;<]2RBW(]HB>:[:.'C4H2E'XHV^YGCXK'5,/C
M*=.=O9S3^36OXGZ2:7_P5F^#>L?MSR_L\P:KJA^(,5S)99-EBP:X2V-P\0GW
M??"AEQC[ZE>N*[;]MK]N7P#_ ,$_OA#!XV^(EW?VVCW>HQ:5;K96WVBXGN)$
MD<*J9'1(G8G/ 6OYD?"/Q(^(&A?%N#]JZ2%Y!:_$J.[FNMQ N=3=WU"2#/\
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M.M6O+_P_X6\.:%?:CQ=W.G:9#:RW7.[YV106YYY)YKEHXA0I3IV^*WX'HXO
MNMB*-=.WLVWZW5C\AO\ @[X_Y WP _Z[:_\ ^@Z;7M_@C_@Z(_9UO%TC25T+
MXK?:9?)LU)T>SV;SM3K]KSC/M7Z)>,_AEX;^(ZVX\0^'M#UX6>XP#4;"*Z\C
M=C=MWJ=N=JYQUP/2L2+]F;X;P2JZ?#[P0CH0RLNA6H*D="#LKH6*HNC&E5BW
MRWZVW9Q3RW%1Q=3$X>HESVNG&^RMW.0_;Z_:HU3]C']E[Q#\0-'\#:[\0K_1
MU79I>EKR@;.9YF 9D@3&7958@8X RR_DM^W1_P %C_V/_P!O[]E_Q!_PEOP@
M\3V_Q5FTUXM)NTT^T%W8WNPB%UU!) [6Z/M+*Z88 _NSQ7[GUYM>?L;?"'4/
M' \3S_"KX;S>)!)YPU:3PS9-?!\YW><8]^[/?.:SPN(I4]9Q=UU3M\C?,L%B
M<1[M*:46K-2C?YKS/B?_ (-AO@?XZ^#_ .P7JM[XNM[[3=*\7:^^K>'K"[5D
MD6U,$4;7 1N525DRHXW!-XX<$^<?\%>/@Q\1/V%/^"C7A+]L[X=>&KGQ=H%M
M:QV?C.PMPQ>%4@:U=Y-H)2*2U**)=K+')""W50?UHI",BCZZ_;RK-?%NO(3R
M>'U.&$4FG"S4NJ:Z_P# ['YC3?\ !UC^S\O@'^T$\+_$U]=\OC2386H_>>AF
M\_9LS_%C=C^#/%<__P $8OV3/'?[1W[:_C7]M+XE:,?"L/C;[5_PB6BS$FX\
MF8)$MP20#Y26R>4A(!EW,X"KMW?HM'^R'\)X?%W]OI\,/AXNO>9YO]I#PW9B
M[WYSN\WR]^<]\UZ)52Q5*,'&A&W-NV[Z=B*>6XBI5C4QM124'=)*VO=_Y'Y7
M_P#!V;_R8]\/?^QYB_\ 2"\KUG_@IA_P2BT[_@I9^Q-X+ET?['IGQ/\ "6@V
MTN@:A*-J7B&!"]C.W_/-S@JW/EOR.&<-]P>,/ &A?$.PCM=?T72=<M89/-CA
MU"SCN8T?!&X*X(!P2,^YK4@@2U@2*)%CCC4*B*,*H'  '85$<9*$(*&CBV_O
M-*F4PJUJTZVL:B2MVM<_FZ_X(1P^)K#_ (+<>![#QD-33Q+HL&JZ1?0ZCN^T
MVK6NCW-LL+[N1Y:1+&!V" 5_217-V_P;\(6?CQO%,7A7PW%XG<DMJZ:9"M^Q
M*;"3.%\SE/E/S=..E=)3QV+6(FII6TL&2Y6\!1E1<N:\F[_=_D>'?\%$_P!J
MC4/V./V3_%/C?2=,35-6L+"[-BDF3##.EG<3QR2 <F,-"-P!&0>HK\B/V%OV
M%/V@/^"POPIU3XSZC^U7K^AZTNKSV<&GQS74QM)(PK<K#<1):*=X*I'&1M(.
M.<5^Y/Q3\)>'?'7PXUW2/%UKI]YX8U#3[BWU6*^(6W:U>)DFWL2-J^6S@MD8
M!/(K\D?BE_P;R_$/]GW6[KXA_L@?&O5-*%Y$+RTTB;4WM7NH2-Z1QWL)\JX1
M@?D69 I!&YSDFNG 5J<8.-^63ZM77IY'!G>$K5*T:CBZE-)WBG9W[]+GZ%_\
M$V?@G\:?@%^SR/#_ ,<?B'9?$?Q/;WLOV.^@1W>WLQA8TDN'"R7#'!?>ZAAO
MVDM@&OF#_@J5_P %3OB/I/[4^B_LM_LX6%M/\7/$0A&H:Y<JDD6A++$9MB(P
M*[U@ F>1U94C(PK,?DD_X-^?^"HWQ"_;P\.^._!_Q26UOO%?P\^RNNL0VZ6\
MFH13-,C)/&@$8E1XOO( &#\KE2S?.'AOQ-9?LD_\'2_B2]^(-PFF:?XZ22/1
M]2NR$@_TRRB%N=YZ*9(VML] _'3-53P[6(J>U2;BF[=&S.OCHRP-#ZK)J$Y*
M+D_B2UOJ^NEKGI%__P $;?VU/#=D_BO2?VR?$.H^.$4SG3+B_P!173)I!SY0
M9Y7C*9X :W"^P%>L?\$9_P#@KIXF_:V\;^)?@K\9-(CT3XS^ DG^U31QK!'J
MRV\PAG#1#Y8[B-RNY4^1@2RA0I%?H/>7D6G6DMQ<2QP00(9)))&"I&H&2Q)X
M  ZDU^'G_!-G78/VKO\ @Y+^(GQ'\#?Z3X,TN36+Z:]A'[BZMS!]ACD!Z$33
M.LJCJ1DXX.%3F\32J>U2]U73M;Y:=RL126 Q-#ZM)^_*SBVW==];['<?\'/'
M[6_Q0_9M^-GPFM_A]\0O&7@N"]T>\N;J'1=7GLHKIUGC"M(D;!7P,CY@>"17
MV%_P1H_X*P:1_P %+/@BT&I>1IGQ/\)011>(=.4A5O 0%%] O_/)V!W+_P L
MW.T\%&;XC_X.8T2Z_;Y_9JAD59(V10R,,A@=1A!!'I7"?\%#/V4_$?\ P0J_
MX*#>%OVAOA3832?"[6M4;SM-A<QPV+2Y-UI4A&0(94WM"2#M*XP3""W3&A2J
MX6G3>DVFT_1['GSQN)PV8U\0M:47%279-;KT/<O^#?S]J#XD?&_]O#]H#1O&
M7C[QCXKTC1(Y3IUEJ^L7%Y;V.-0=!Y22,53Y0%^4#CBNF_X."_VM?B/IGQL^
M#G[/7@+Q6_PXM_BE<0MJOB9;M[3:LMT+6.(S(0T<*'<\NTY8%!D#<&\,_P"#
M7;Q3!XY_;C^/NMVJ2QVVL:=]NA24 .J2Z@SJ&P2,X89P:_1[_@IU_P $Z/A?
M_P %(O!.@^$?&FJKX=\76[W%QX7U.VDB_M"(A5-PB1.?W\.!&9$'3:AW*>:R
MKNG2QUYK1)?+3>QO@85\3DSC2E[S;Z[KFVOTNM#X]^"G_!"W]IK]D_XT>&->
M\ ?M47$^GF^C;7TO[:Z6,VXY?_1'FFANB<;0)#'@L"&&,C[Q_P""FGC'5_AY
M_P $]OC)KF@ZG?Z-K6D^$K^ZLK^QG:"YM)5A8K)'(I#*P/((.17Y+?M S_M>
M?\&^.J>%]5'Q7A^*/PFU*^&G6MCJ<LD\#;$+_9FMYBTEH2BL5-O*5&TY/\)_
M3+_@H!\2[;XT?\$;OB3XQLH);:S\6?#.;68(93\\4=Q8B95;W < _2HQ$9RJ
M4ZDFI)O1I6Z]3HP$Z,*%>A3A*G.*NXMMVT>J=V>4_P#!MO\ &[QE\??^"?VJ
M:WXY\5>(O&&LQ^,;ZT2^UK4);ZX6%;:S98Q)(S-M!9B!G +'UK\^?^"@?_!5
M?XS_ +%?_!:#QQ=:/XW\4:IX1\+:Y;Y\(WFKSMH]S;/9P&6 0%C&FX.Y5@N4
M<AAR*^W?^#5S_E&MJ_\ V/.H?^DME7RI>? ;PQ^TS_P<U?%+P'XRTV/5?#?B
M6SOK6\@;A@#H<961&_AD1@KJPY5E4CI7125..+K.:NDGI]QY^*=>>6X14IM2
ME**O\GN?I3XT_;AT+]JS_@D?\3?B_P##+6;ZP)^'^NW=O+#-Y.H:#J$&GS,8
MV9#F.>&0*05/]UU)#*3Y]_P;L?&7Q=\=O^"=%OKWC;Q/K_B[6V\1ZA;G4-8O
MY;VY,:^5M3S)&9MHR<#.!FOR@^(.H_$K_@A;\6/C=\#M=%WKWPY^+?A+5=+L
MI<;(=02YM)X+/4H@>$EC=Q',@[!Q\V(VK].O^#8+_E%Y;?\ 8TZG_P"TJQQ.
M%C2PTI0UBVFGY6.K+LRJ8G'PA57+.,9*2\[K7YGCUA^T_P#$A_\ @Z;?X<'Q
M[XQ/P^WN/^$:.L7']D\>%#<?\>V[RO\ 7?O/N_?^;KS7ZY5^*>F_\K@;_P#7
M23_U#37[65RY@DO9V_DB>CD,Y2^L<SO:K/\ 0\J_;+_9-TC]M3X%:GX$UK6_
M$F@66HI*#<Z+>&VE)>WF@VR#!$L6)F)C;Y6*KGI7X\:W_P $AOVZOV=-7N?A
MS\+/'_C_ %+X6R.T"WEGXFM=*MTA8X8I:/J&^/()R$VY[U^[E%9X?&U**Y8V
M:[-'3C\GH8N2G-N,EUB[.W8^2?\ @D?_ ,$K?#__  3#^#NI6EOJ5UK_ (Q\
M7M!<Z]J<\*P?ZI6\JVCC5W"I'YDG.]BS.QSC:JZ7_!3?_@E!\/O^"G'@.RM_
M$,MSX>\6Z$CKHWB.QB62>T5N6AEC) FA)YV$J0<E67+9^I**R^LU?:^VO[W<
MZ%EV&6'^J<GN=OZ_,_#%?^"*_P"V=X^UA/A?XD^+'Q!'PA1Q:_;+C78KJS:W
M!P,V']H[B@'2,Y ["OU,_P""=W_!-WX??\$V/A#+X:\%Q7%[J&J.D^M:Y>A3
M>ZO,H(7=@82-,L$C7A=Q/+,S-]!45K7QU6K'DEHO+0YL%DN&PL_:PNY=V[V7
M9=C\YO\ @L7_ ,$P_'W[;_[5_P 'O&'A2/?I?@A4%\=UN,8O$F/^LGC;[J_P
MJW]*^V?VI_V;O#O[7G[/OBGX<>*X6DT7Q39-:2N@'FVK\-%/'G@21R*CKGC*
M#/%>@45E+$S<8Q_EV.J& HQG4G:_M-_NL?F7_P $+O\ @DOX_P#^"<_QQ^(6
MK^+3YNFZ[I4>GV4V+8><4N-^[;%<2L,KSA@/K7<?\%EO^"2VO?MKZGH?Q.^'
M/C#Q9H/Q2\$VHMM*M+.^"6]PF]FS"SS1"UFRW,JO\P4 J2 1]^45J\=5=;V_
MVCFCDV&CA/J5GR>NO?<_#WX"?\$,?VE?VT/BKI,G[67C+Q[#X3\-OYD%O?>(
M;;6Y;Q,C=%$Z7DOV<N -TGEL<#UP1^KW[9/[/DWQ8_87\??#+PG:Q6DNL>%;
MC0=)MH@BI"#!Y42+O95  P!E@..M>R44JV-J59*3LK;);#PF48?#TYPA=N>[
M;NW\SX\_X(B?L2>*_P!@7]CR_P#!'C!-FJW'B6ZU51F$_NI(+9%_U4LJ]8F_
MBS[>OF'PX_X)E>//"W_!=CQ!^T+/'_Q1>I+.(GW6_P#'IB6PX$YE^^IZQ#\N
M:_1*BE];J<\Y]9*S^9?]ET/9TJ6MJ;37JNY\O?\ !67_ ()S:%_P4<_9=O\
MP_<0>3XPT%9-0\+ZC$B&:VN@O,.7908I@H1@S!<[&SE :S?^"+G[&WB?]A/]
MBN'P'XN39JZ:W>7Y&8C^[E\O;_JI)%_A/\6?85]9T5'UB?LO8_9O<U^H4?K/
MUM+W[6^1^<UG_P $PO'T'_!?IOVCS'_Q1!=FW[K?OX>.G]//\W_6_P#3+]/F
=K]&:**56O*I;FZ)+Y(K"X.GA^?V?VI.3]7N?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>image02.jpg
<TEXT>
begin 644 image02.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" !; *$# 2(  A$! Q$!_\0
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M[/<_4:L[Q9XGMO!GAVZU2\CU":VLTWR)86$]_<,,@?)! CRR'GHBD^U?E/\
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M%%% !1110 4444 9'C_^PO\ A!-;_P"$I_LG_A&/L$_]K_VKY?V#['Y;>?\
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M<_K[@A@<5%+][VOO\[-M]^VME<^#_P!L?_@HQ\2O@A\<O%7A!?&7PXTO7XO
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J*Z<7%W>EOPZ>E]?7YW****Y3TPHHHH **** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>image03.jpg
<TEXT>
begin 644 image03.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1"  H B8# 2(  A$! Q$!_\0
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MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]_***\O\
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M^&/&GQ$T6;PYXT>;X8_9?[9(?2HKC_2)+*.,QV4E\E\4#7\ :1K=8U8.I;>
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M(.J7&HZI%KNI1/+IT46IZC%H2:'%=R".S4JZVZR2!(BD1FG<E"BQQQQ>%O\
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MNVK:?<)<6D5W!-!<M!;NP:.495X492".>#6<G74;RV^7E_P#>G'!2GRPW?\
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MZV\2:%%XI\.W^F7#2)!J-M):R-&0'574J2"01G!XR#7R[HW_  27T#PY\/\
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M[^QT7AO]@V[\'_$CQ7XLTSXU?%BTUSQQ;6D.MSBV\.R+?26MO]GAGV/I15)
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MSIX1_9RTC5+/PGI]W;?VY?MJ>IW=_J=WJE_J5RRJAEGNKJ26>5MB(HWN<*H
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M"<OP>^&$,::5X8OV-O)I+VTFH>(=3U*6R32[D76GP0/<7$C0V\,P#B",K$<
M,A'%%%'MJG\S']5HZ>XM/)=K?EIZ'2_!_P#9/\(_ +Q3/?>#TU;0=.N3?S2:
M%;ZA+_9#75[<I<W%W]G8D><7C55.=L2%UC5 [[N'@_X)9_ R#PYKVD_\(??R
MZ?XBA>VN8IO$NJR_9HGOEU"2.T9KDM9H]VJS,ML8PSJ"0<444>VJ)W38GA:#
M5G!6]$>U^ O ]E\-_"-GHFGS:O<6=@K+%)JFK76JW; L6/F7-U))/(<L<%W8
:@8 P  -BBBL[WU9NDDK(****!A1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>image04.jpg
<TEXT>
begin 644 image04.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" !" $T# 2(  A$! Q$!_\0
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0H **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140186929192448">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document And Entity Information<br></strong></div></th>
<th class="th"><div>Nov. 16, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity, Registrant Name</a></td>
<td class="text">BIOCARDIA, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document, Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document, Period End Date</a></td>
<td class="text">Nov. 16,  2023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity, Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity, File Number</a></td>
<td class="text">001-38999<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity, Tax Identification Number</a></td>
<td class="text">23-2753988<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity, Address, Address Line One</a></td>
<td class="text">320 Soquel Way<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity, Address, City or Town</a></td>
<td class="text">Sunnyvale<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity, Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity, Address, Postal Zip Code</a></td>
<td class="text">94085<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">650<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">226-0120<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity, Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity, Central Index Key</a></td>
<td class="text">0000925741<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=bcda_CommonStockCustomMember', window );">CommonStock Custom [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">BCDA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=bcda_WarrantToPurchaseCommonStockCustomMember', window );">WarrantToPurchaseCommonStock Custom [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Warrant to Purchase Common Stock<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">BCDAW<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=bcda_CommonStockCustomMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=bcda_CommonStockCustomMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=bcda_WarrantToPurchaseCommonStockCustomMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=bcda_WarrantToPurchaseCommonStockCustomMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>bcda20231116_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:bcda="http://www.bcda.com/20231116"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="bcda-20231116.xsd" xlink:type="simple"/>
    <context id="d20238K">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000925741</identifier>
        </entity>
        <period>
            <startDate>2023-11-16</startDate>
            <endDate>2023-11-16</endDate>
        </period>
    </context>
    <context id="d20238K_StatementClassOfStockAxis_CommonStock">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000925741</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bcda:CommonStockCustomMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-16</startDate>
            <endDate>2023-11-16</endDate>
        </period>
    </context>
    <context id="d20238K_StatementClassOfStockAxis_WarrantToPurchaseCommonStock">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000925741</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bcda:WarrantToPurchaseCommonStockCustomMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-16</startDate>
            <endDate>2023-11-16</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="d20238K">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="d20238K">0000925741</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="d20238K">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="d20238K">2023-11-16</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="d20238K">BIOCARDIA, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="d20238K">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="d20238K">001-38999</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="d20238K">23-2753988</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="d20238K">320 Soquel Way</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="d20238K">Sunnyvale</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="d20238K">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="d20238K">94085</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="d20238K">650</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="d20238K">226-0120</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="d20238K">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="d20238K">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="d20238K">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="d20238K">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="d20238K_StatementClassOfStockAxis_CommonStock">Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="d20238K_StatementClassOfStockAxis_CommonStock">BCDA</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="d20238K_StatementClassOfStockAxis_CommonStock">NASDAQ</dei:SecurityExchangeName>
    <dei:Security12bTitle contextRef="d20238K_StatementClassOfStockAxis_WarrantToPurchaseCommonStock">Warrant to Purchase Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="d20238K_StatementClassOfStockAxis_WarrantToPurchaseCommonStock">BCDAW</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="d20238K_StatementClassOfStockAxis_WarrantToPurchaseCommonStock">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="d20238K">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>14
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MW&,EC'%BM/XU@LD/['X 4$L#!!0    ( .N)<%<ZJJ+G0 $  #P"   /
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M-Y-;2>C@W(-@[^&5C!W-CQ]W]P-02P,$%     @ ZXEP5R0>FZ*M    ^ $
M !H   !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<[61/0Z#, R%KQ+E #50
MJ4,%3%U8*RX0!?,C$A+%K@JW+X4!D#IT8;*>+7_OR4Z?:!1W;J"V\R1&:P;*
M9,OL[P"D6[2*+L[C,$]J%ZSB688&O-*]:A"2*+I!V#-DGNZ9HIP\_D-T==UI
M?#C]LCCP#S"\7>BI160I2A4:Y$S":+8VP5+BRTR6HJ@R&8HJEG!:(.+)(&UI
M5GVP3TZTYWD7-_=%KLWC":[?#'!X=/X!4$L#!!0    ( .N)<%=ED'F2&0$
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M;W!S+V%P<"YX;6Q02P$"% ,4    " #KB7!7A>^L<NX    K @  $0
M        @ &O    9&]C4')O<',O8V]R92YX;6Q02P$"% ,4    " #KB7!7
MF5R<(Q &  "<)P  $P              @ ', 0  >&PO=&AE;64O=&AE;64Q
M+GAM;%!+ 0(4 Q0    ( .N)<%="G2"6N@0  #$5   8              "
M@0T(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4    " #KB7!7
MGZ ;\+$"  #B#   #0              @ ']#   >&PO<W1Y;&5S+GAM;%!+
M 0(4 Q0    ( .N)<%>7BKL<P    !,"   +              "  =D/  !?
M<F5L<R\N<F5L<U!+ 0(4 Q0    ( .N)<%<ZJJ+G0 $  #P"   /
M      "  <(0  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " #KB7!7)!Z;
MHJT   #X 0  &@              @ $O$@  >&PO7W)E;',O=V]R:V)O;VLN
M>&UL+G)E;'-02P$"% ,4    " #KB7!799!YDAD!  #/ P  $P
M    @ $4$P  6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     "0 ) #X"  !>
%%      !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>3</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>2</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="bcda20231116_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bcda.com/20231116/role/statement-document-and-entity-information</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>bcda-20231116.xsd</File>
    <File>bcda-20231116_def.xml</File>
    <File>bcda-20231116_lab.xml</File>
    <File>bcda-20231116_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="bcda20231116_8k.htm">bcda20231116_8k.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="25">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>19
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "bcda20231116_8k.htm": {
   "nsprefix": "bcda",
   "nsuri": "http://www.bcda.com/20231116",
   "dts": {
    "schema": {
     "local": [
      "bcda-20231116.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/currency/2023/currency-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/exch/2023/exch-2023.xsd",
      "https://xbrl.sec.gov/sic/2023/sic-2023.xsd",
      "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd"
     ]
    },
    "definitionLink": {
     "local": [
      "bcda-20231116_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "bcda-20231116_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "bcda-20231116_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "bcda20231116_8k.htm"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 1,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 2,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2023": 2
   },
   "contextCount": 3,
   "entityCount": 1,
   "segmentCount": 2,
   "elementCount": 30,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 25
   },
   "report": {
    "R1": {
     "role": "http://www.bcda.com/20231116/role/statement-document-and-entity-information",
     "longName": "000 - Document - Document And Entity Information",
     "shortName": "Document And Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "d20238K",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcda20231116_8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d20238K",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcda20231116_8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.bcda.com/20231116/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "bcda_WarrantToPurchaseCommonStockCustomMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bcda.com/20231116",
     "localname": "WarrantToPurchaseCommonStockCustomMember",
     "presentation": [
      "http://www.bcda.com/20231116/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "WarrantToPurchaseCommonStock Custom [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityDomain",
     "presentation": [
      "http://www.bcda.com/20231116/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity [Domain]",
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.bcda.com/20231116/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://www.bcda.com/20231116/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://www.bcda.com/20231116/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.bcda.com/20231116/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.bcda.com/20231116/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.bcda.com/20231116/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.bcda.com/20231116/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.bcda.com/20231116/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.bcda.com/20231116/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.bcda.com/20231116/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.bcda.com/20231116/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.bcda.com/20231116/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document, Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.bcda.com/20231116/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentInformationLineItems",
     "presentation": [
      "http://www.bcda.com/20231116/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.bcda.com/20231116/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.bcda.com/20231116/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.bcda.com/20231116/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "bcda_CommonStockCustomMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bcda.com/20231116",
     "localname": "CommonStockCustomMember",
     "presentation": [
      "http://www.bcda.com/20231116/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CommonStock Custom [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.bcda.com/20231116/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.bcda.com/20231116/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_DocumentInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentInformationTable",
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Table]",
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.bcda.com/20231116/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.bcda.com/20231116/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.bcda.com/20231116/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document, Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.bcda.com/20231116/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.bcda.com/20231116/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://www.bcda.com/20231116/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>20
<FILENAME>0001437749-23-032364-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001437749-23-032364-xbrl.zip
M4$L#!!0    ( .N)<%>DBFW5G@,  "D/   1    8F-D82TR,#(S,3$Q-BYX
M<V3-5]MNVS@0?2^P_\#JG:;EH$$MQ"F*9+<PD&R#)L7N6T!38YNH1&I)JDG^
MOD/J8BN18]DH@GT2R3EG;AP.J;-/CWE&?H*Q4JM9%(_&$0$E="K5:A9]OZ6?
M;R_F\XA8QU7*,ZU@%BD=?3K_X]W9>TJ_@ +#':1D\43NUJ5*P5SJ',B--HYG
MA)(X9O$IFXPG)^1C,CE-XBFYN:;4\Q]MFEBQAIP3=$+9Y'%A,CF+ULX5"6,/
M#P\COS+29H4*QB=,*N^&@*C!V[2#?CAIL#'[]_KJ-NANP9E4/_K@\70Z94':
M0*TK3(L,+E@0HY7^R;PD!-- 7RCM>NS%"VY;CU-GJ'LJP/9S4,R\V)L8TW%,
M)W&TE9O4=;VJS7Q@E; U K+?>Q1TG!>Z5,X\]8-K88=@I=B1%RFZFDMCL(QV
MJ:ZE'0H\BG4_W$LZT(5(>2>!?F$D=!Y0<1R?1H0[9^2B=/"7-ODE+'F98?9*
M]5_),[F4D&*=9Y"#<AW EMAQLP+W-\_!%ES 'H--0<N\P-(GJI>VJYRK4W"E
M!7?A&.ZD^!EM>-0OT7A"3^(1FH[8P3Y,F=$9, 4K?X:'^9$9TV%Y+Z;>B_AT
MH!>[3E2?=;L3'T;4CXX)OO>D[7)@'S/,[2'1OSBY RN@(?BD?S@FW9L6,"C;
M#=P/#LGU*YUDD-UM2C,YVOZF.0VKL!KN!\?'W&UQPX+>YK2SHUW8:IN#S+?X
M,.J:K0USI;0+.AI7>%%(M=1^ZN^ZI+GPOL&2A#LUX4;X=O'ZS<L*HPLP3H+=
MOC.#@K6!Y2SR'9<VW?8^XXL1W@4-Y(6!;M<,[0HID%UMW&NX_NS.(HLYS:!*
M\5L&DL+RT$"0(I7TF_"_BZ8P<&@T2+%X"?/#XO'4.Q01B2] O U=N,EIJD49
M!OA8I?B5[HGZ\C1YT!\1S_O^;?[Z75XY-EQKZ]5F9ZJ'RI"'X?EX/,9G\F5M
M8WOX6:7DSV".S#?FSM@S6ZWYTD+Z59V'L>"9*+,VJS6I1O01NE6U'_]\WUXP
M6&>CPLJSAL'Z6TK]+"-\89WA A]ESI18=GZK_5[=-PG"_%3IF6]OL>^*LV@/
M1F;8#GQQ5JIMB;:D*[WTB]%E,8O"OT@BL03P)1B*L%I!G_#7:([K/BPLT["*
MAT3J]"[@TM)49MC@B"YTGFMUZ[3X<5%:I_-KR!=@FF!VBX^)H_T'25*=<ZE^
M<RS_<&.X<G?ZIC1BC26^)[@#\&\;+=O\G^+T%U!+ P04    " #KB7!7Q$IW
MZG,%  "4-   %0   &)C9&$M,C R,S$Q,39?9&5F+GAM;-5;76_B.!1]7VG_
M0S;['-+0;7>*AADAVAFAH5-4&,UJ7RJ37,"J8R/;*?#OUPX?I4.<&$JB[ L$
MY\0^Y_KZ^L97?/R\C(GS EQ@1MMNT+AP': ABS"=MMT?0Z\S[/9ZKB,DHA$B
MC$+;I<S]_.GWWS[^X7E?@0)'$B)GO')&LX1&P&]9#,Z <8F(XSE!X ?7?O.B
M>>E\:#6O6\&-,[CW//T\P?2YI3_&2("C>%"1_FR[,RGG+=]?+!:-Y9B3!N-3
MU<7%I;]%NQNXOAO)W0/[X"M_?7,'/>AZ<9EB@YN;&S^]NX,*G 54G0;^/_?]
M83B#&'F8:J.$FHO +9$V]EF(9&K)0@F.$:%_>5N8IYN\H.E=!HVEB-R=X1 /
M.2/P"!-G<_GCL7=H"4RE'^'8WV!\1(@BG/8PXS Q$MV:3X]_I4?^<^])N9HK
M/Q XGA-P_?=2BEB,,/5BB,? 3R27V<>9:>(8J%XFWGJP4YD:NCDOV9GJC8?)
M&+S=>"?RS>FI-/O"!"5$OM_ ;_LQT-UR_96H'FD<1J@1LC@-8$&@(EE*52U\
M"6H4J>8P3-(+%1X]]8WE2@6&">-Q&@?>2M"]>=N>4JY'=V30H)1BBC6PKWYN
ML)IJ*6K6)& I0<7[O9!$6'@P96([Y0+"QI2]^!'@='Q]D1IC/6F G^[2 6_?
MK J"QD#:KNGVF@G149?Q/7M4QR3;R<[.Z'8S,[W7V1BA,8$,=D70ZA@J7X2>
M<BUAQ_( 7A+3/DP16<]A9XFSR!D0)5MNI+K/L=3^[9*9#(!C%MW1Z%9%AAQ*
MF;A2U^0C3+&0'%'Y'<59U/)@I3+KJ:R9SQE/77FH0VJ7)53R59=%9J)63Y7*
M^PLF\#W93YL.2!Y"2F4T0LM>I'>?"5YGTP7T"O"E<NU$$0<A-E\Z@@5&GCG8
M*CAVU>4#'[&%>4LS(JO@EWK_ Q]P]H+7KU6Y) WP*I@.F$J9R+]XGKNT\\ E
ML=03U^& #+RR;I>UQZH.R6#&J#FVF" E,?K)L50):Y?%<4(W@2)K[\_%E<1M
MR @.5?I.I_?*J3E&)(.8&502JP$';050JRO-/W2VSQ\FD\S9+ 97P[(G1 +\
M**[&1\J:;0@3Y62KH#D>89F9PYL@)3$:<:0/_(:K>,RR7"_S?LG6N5N&,T2G
M8,CS\F"E[@%W,?"I,L97SA9RIOQHCNC*N GDHDOBV5%.'6G'_D+0-(-9YOU2
M;=95@W%$>FJ%+;^!V5H&W$G<)DB,TT.B1'A3A.9K@D"DV+:\,MTT/ VW)R%=
M@H1XF PE"Y\SWA&M\94QWR>0>6Y1#/P_<#WUM.7PY$VW/.E=0+]VJ?Z[B9 L
MOH>,9,4&^DXB/Q'7+ZLC-DBXBF<"CF!V[+,FJJ]GB!T>.HRKW;#M7JBGTO/5
M5DB8@*CM2I[L NWFZ/;TL_,)9W'^D0LK.OQ30Q2)",XNXJT7GJ0BVY4MU#2K
MF!+[",?L8XN%N,M*INI,ZO*GL(IUE5.<>77*P@-A9G'J6=TR.YNF(W?I*N<M
MLUSYUC=S%A,[9D^J,#Z>1=1IV]G[)F_3R*B$I;PCJ;.T70%3?7&T'?8*Y;D.
MVS^H=[!C*CBUF-A3I1T6,RK<^<XO)Z<04N&F=SY=Q544"UE_U536$347"Y57
M-55I*MI82+JNJ22K0H^%OK]KJJ^P0&2A[4.]M9E*2Q;*;NJM++<>9;-7EY]:
MODM?3AW+1EW]4A%S-<Q&3_URD?QZFHVF^N4A%L4X&V'URT2*BGDVJNJ7>=@6
M 6W4U2\).:YL:*.Q?HE(?N'11E/]$I"<ZJ6-H/KE'<6U3YN7Z;KF&Q8E4QMY
M]4LX<NJN-H+JEW%8%&WWSN7\7[2I;I\_[=KUA_Z_BVKY#U!+ P04    " #K
MB7!7($^.8;8&   /10  %0   &)C9&$M,C R,S$Q,39?;&%B+GAM;,U<:V_;
M-A3]/F#_@?.^;$ 550E6+$'3(G#3PEC2&+6+#BN&@I9H6ZBD:U!T8__[D93\
MD$WJ99/:ET:6KLZY.O>(#U'JZ[>K.$(_"$U#2&Y[WL7+'B*)#T&8S&Y[GT?.
MW:@_&/10RG 2X @2<MM+H/?VS<\_O?[%<3Z0A%#,2( F:S2>+Y. T'<0$S0$
MRG"$'.1YKO?*O7QY>87^O+E\=>-=H^&CXXCSHS#Y?B/^F>"4()Y'DLJ?M[TY
M8XL;UWU^?KY836AT 73&(5Y>N9OH7AXNC@9L>\)^\!]N=G ;>@3]?"5CO>OK
M:U<>W8:FH2J0@WKNWX\/(W].8NR$B1#%%[FDX4TJ=SZ CYE4LO(2D#9"_'(V
M88[8Y7B7SI5WL4J#WE8X"A'Y1*9(_/W\::!EO'9%A)N0F:C3 YZ0B&<L(>:4
M3-7G19063A-97(LLO%<BBU]5:&R]X.9(PW@1D9Y[8IY#0D,([I,S)ZR&-9#Y
MB&'*3.1^#'S6[,? ;]OSYGT,>=Z,>=M%SISQ$>19,_Y(SNR,0\!S9=LB37:<
M8JW<(A'SP+?R, %7THA*MKS)WH,E*T9X%[372D;@'Z6?;GJ*E/@7,_CA!B24
M/938<,2&S)S_^':?L)"M>8^&PV1#)5.][>D.9YE$HB, >GB%Y1!.M*]4+0F.
MI:4DA27ULRZ2,XE^G"3.YU'O3<:%OF9L_[YV=\D4T[RC&]4P]2ORR"-<'WA?
MN&#%:YA2B$ND@BH-LDOB%%+(,Q7U@=\U4<9YMPI315TU$0U+>X!BNKJ2#FUJ
M+!CM5E@G&M10PTB=WX&_C$G"!LD4:"S'9;R%(0-&8E71ZX0W=$ 9I&D[;+C1
M'CGZ*NB1Y+=KCEKB0E/5;-EFC"<1J6>90NCI=I%PW5A%4G?NDJ*>>H<HA#+J
MCC$'+W'$_N&6+A 0MBK_ @FV3FI=4 JJ)#!:T^WL\!T?59<45QG7LLH%+'OE
MSFCY:"% @KB3RJMEA-KZ&/%"-D+Y1&9ARBA.V$<<JZQ0%M9J!E"$LC,3>(%V
MK$C0=C CT$@(=;4Q:()!X@-= )7]RXAQ__5AF3"Z[D.@]T2MLUI9I!39EF,*
M2;Q ,@T$%.6I()%+!S:JISJTE-.@R=Z'$?FXC">$:AUU'-+*/CL86UX1C"BC
M[, 2"MF@CAX&BSW&JT' .[5P&F;K!!65KXAO90,-IBU/<'I4Y._.(57R0F/=
M#'KG+@BXO&G^1TR(/:UO2F);>4:!9\LO.>=V \DG&$])%YU,F:S02"_S/NGS
MS2<ZAF?]<VMMY"D>V:%9=XB@%D,10=Z=.Q1RJKRAT\F\,^10YXD.*?P(L^7K
MTH)JPD_QR &D=:-L!ZV;#+ISBTY=E65*93/OFR&D#$?_A(O2Z4]9\"F>*0!:
M=TS&CCA]5Q.<4EU5;BD1S(A71(-V1PG6N$-UN*$?]B%,.T#V)8+,?KV52D&5
M!&962GEIHN$<$OT451?2=*WT ,;X8JG@0Y*PB_F'5C6H(X>16G^A(6,DZ4,<
M+Y-\BJ-:)BV-:UAU)9;ITN>DJ,AJM?SE&D)M<8P88011Z(<L3&:/?+Q!0QPI
M7* /:FB!8R#3]=\QH@VEU>*72 ?U-#%2]B$EPFJ$YRZ7WL2+5/1I.E6V^M7!
M#6V@!S1M!\[L^'O4*.-&DMRJ,6J("LW4LF&409HN"6UD%^TIIYGF"-:Z=;(,
M_C<.TNNL]E&%@&9Z&^(O>4>W]BXGXY IW[+1A33M:0Y@3+M#DB"8(N_RM\GO
M:$-OMZ_120=U-#%2\#'%XN.2T3J>@&IDH3S>L-0%#.-USLA0QF:UO&JMH%($
MHW?R_<J?<WV(YLV)LK"6=_0^E/'18\Z)-J3V7YPH51#J2F/P@>%]3.B,6^\#
MA6<VYSW, B=K[1/#TNA6CPR5B+:>&6[(4<:.<OH.'AF6"PL-%3/BESL^[ C$
MT.-]A&<*ARB/-_1$ <.T"[9D2+!9+;I:*Z@4P6!#T.>$%$<#/J!<_47T38 F
MKM7-?X!EZ[;/:9'D19RX@QM>)R/4UJ>%%Z8XG<A\EZDSPWB1&8)$+-WLV3DC
MW_%-KF0)-_8CG*9/TQ$#_[OB6YS:\0V<4HEI?&E!\(EY@62T_:5.?4FAL5:6
MW+.?A/+3O.K %GXY!K-M%-N?[=60$>KK4\\<$S_ LN*>EW] *O9\$T\IQ$N:
M'+N_3!G$CT2Q'E4GM$'ER^",UWY'BS)>]#5CME?_6G)"$YU.\L 73,4KX&,8
M<LWF."4-3-'TW*8NJ8MO?&VK)(]N?=2X G"2M(=.X]>W=[D/?.O-;E>8_5<;
M?,]_4$L#!!0    ( .N)<%=*-=JH @4  ',T   5    8F-D82TR,#(S,3$Q
M-E]P<F4N>&ULW5M=;^(X%'U?:?]#-OL<TM"=[H"&&2':&:&E4U08S6I?*I,8
ML.K$R'8*_/N]-A]#19R8CH(&OQ2PC^WCXVO[YM[TPZ=52KT7S 5A6<>/&E>^
MA[.8)22;=?QOHZ [ZO7[OB<DRA)$688[?L;\3Q]__^W#'T'P!6>8(XD3;[+V
MQO,\2S"_92GVAHQ+1+W BZ(PN@F;5\UK[WV[>=..6M[P/@A4>TJRY[;Z,T$"
M>\ C$_IGQY]+N6B'X7*Y;*PFG#88GT$75]?A#NUOX:HVD?L&A^!WX:9R#SWJ
M>GFML5&KU0IU[1XJ2!$0.HW"?^\'HWB.4Q203(D2*RZ"M(4N'+ 82:UDY10\
M(T+]"G:P0!4%43.XCAHKD?A[X3BC^!%//?7Y[;'_:L1)G*!&S%*M>Q3! BA4
M"'PE3G$F@X3%N?X"JQK )Y%KF,^4\533ARGI,>8<3SN^ZBW8]:1(_'ER1W*]
M ,,1)%U0[(?[.2PX%M!(0P=0L$4KLK7,9T,#KR0&0SW0DK+XU8S5T&)G3P+'
MC1E["1-,]/CJBY9#2P$_GN[T@&#WB.R'HFB":<<W56^84&4NC!\H\I-,!GB&
MZ&:\[HJ( C(&1$U\;K?KTO^Q%F,TH;B 6!7T? S!$G$?#*M(/AMXS4S'T'T)
ML\/JFID,,2<LN<N26]B')90*<35QVYCV(YX1(3G*Y%>4%E$K@]7*K ^7*U\P
MKDUGI ZP'LLSR=<]EIB)6K6JE?=G0O'7/)U@;B1Y#*F5T1BM^HDZZZ=D<^E6
MT*O U\JUFR1PU8GMASHQ(B//$NPY./;@ZP,?LZ7Y*C,BS\%/6_\#'W+V0C;>
M5RE) _P<3(<,'!3Z'UF4;NTR<$TLU<)U.48&7D75=?DKT"$=SN&QPKAY39":
M&'WG1()[V&-IFF?;@Z+($2C%U<1MQ"B)B81'LWLP:DX0+2!F!M7$:LBQ4@&>
M&K4O/E:^-7^83@M7LQI\'I9](7+,3^)J;%+7:N,X!R-;1\W)F,A"G]D$J8G1
MF",5%QBMTPDK,KW"^IK5N5O%<Y3-L,'/*X/5>@?<I9C/0(POG"WE'.QH@;*U
M\1(H1=?$LPM&G2C#_DS1K(!987VMFO5@,(YH'W;8ZA]L5LN >Q.W*1(3'7K)
M13!#:+$AB*D4NY(?3+<%3Z-=W*%'D1 /TY%D\7/!\[8U_FS,#PD4QBNJ@;9<
MCZ-&JN1)G:CJ$0;Z[>5"LO0>%US\-M"?)/(=<?7@-V;#G,/9(/ )S$YM:Z)Z
M&/_J\MAC'.Z6CG_E>U #-PS'R6 SK#%8J -AFAL,I@.>[9@R@9..+WF^/^L0
MCX^B:J\[VB+"!>(JD!;/"4UVK:><I>7A(U85ZH+NJR<>_9H3M]_'S'X'60G2
M=$ 0^[UL)<FU*Y*\[1#9:72Y1TAEH)=91*HO^3BQ%>%$]\'2,G[1(^44R[ /
MPEN9R67ME>.9,MN0MH.;QJB&.1URR1?O6U4HR<!<\J7[MBUR0C+%2IR_7!+'
ME,2Q4N*=2TI8Y8NL9+EQ29;*])25)'\[*(DI'V8ER'L'!2G-O5FITG)0E9),
MGYV#YHB_:DXSVLG@B*-:GM^TD\(1;]4BIVJGAR/N:E4JUTX,1]Q3V\RQG2B.
M>*JGI:CMI''$6RW/C=M)X8B76I*7M]/!$>>T^F4 .SF<\DHM7CVPBY@YXI:6
MO/9@IX,C?JG%JQ8'&8?P2!+H^/GCOD;]4?_. B7_ U!+ P04    " #KB7!7
M@D4]0KH2  !E>P  $P   &)C9&$R,#(S,3$Q-E\X:RYH=&WM/6MOV[BRGT^!
M^Q]XO=N>%(ALR\[+3AH@=9*NT38)'"^ZN%\6M$3;W,J22E*)?7[]F2$E69+E
MQ&[SOBG:)A8I#CGO&0[I@[&:>&0Z\7SYH3)6*FS7:M?7U]7K9C40HYK=:K5J
M4^Q3,9W:@@US':<#X>FNC7I]IP:M24=L<'G:-]_/-"9=?<H=F>\IF5,=!5<U
MW03O-)K9<?G2*31KW)>*^@Y+^TNW;&70UZ[]]?7+I3-F$YITYE-E >C<"\E4
MN.]QG_WUL?>EI@3UY3 0$ZIXX,-8]K95W[.:=@H4NGY?CE!LS8 L7\UM\!I6
M8R?%8.#[T:1\'%>)FIJ%K :=+.C%!'>2]R)I8=,<^4,J!_JMI"6'^T@)-EJ*
M^U8-VN?+6M;/;F:6EIF("+PE$]$M.)&Z5;<S6)8J%.5L@RVYF2_0(\\TV#R@
M,F4:+H.MAKU[$YN9'LD+@.0")LMID"RB8>?D1)7*R;:1$S5G97X[*UM% 5#C
MR'>9<(,)R[W=._YTRF'A(UEU@DF&Q*L1>%JJ,&Z9B\MX.<&@(<]ITAI1&I:R
M S;D.CM!Y"LQ*Q\Y;LR]():PC4"FL?<*7,:=)4S&G?PT(B&8[RR;1]R:>X5-
MG7%Y=VS)=95"+6(#'N8Z#1R7YLB"#Y"\NI=MVSN5PX,QH^[AFW\=**X\=H@]
MDL:_][Y70=D?U$S3FW]!K_^U+/*)^4Q0Q5PRF)&^X:=CX"=R$0A%/6(1VZ[9
M.QH(V6LW=MIVDUQ\)99U^.9@PA0E."6+_8CXU8=*)_ 5\Y75!X&H$,=\^E!1
M;*IJQM34#@]J9I8'@\"=$:EF'C#O$+I:DO^'M8E=#]4^T0^&=,*]69N\^Q$%
M:K_/)TR2,W9->L&$^N;A/@FIZP*KMTF=^Z1>M;F_3X B,A!M0B,5[ ->7'Z5
M0'*Y##T*@X+.9)7#_WESP*=MG!$3R0?NNLR//T"O,Z-8S7*FJH=FTD5\['VN
M$)^B[ &/MX\FS'?AGSKUZ*AR.*2>9 >UW!!KCWGB [EF'1A44*\+M)E^9K/*
M81W^M!K;NUOV(@  42LN FPW0PYE$A^@1FQ++<4 EVB3U1YKZX\<8R4L4P7[
M6HF;4<-]J$@^"3V&1(RAY ?6#V00B?BSMN?M>(F$N_,ESEN97N'\,W?QR9 S
M0?046:G![G0_Y[%0?%E/L!Q""(@*W/EG4&-"'8,('.+D+-NV[)WDW7E;9L+N
MDLY)RQST'%0MAPM#IJ7H^?M2P3C(2AV/2GD^O%2!\_UHRN7?G6 R"7S]^6&0
M&..!C7 ZR0,70$Y#CSM<?663 8!Q039]"1[,ATJLQMM+%U'1BJF=64HGDBJ8
MF*$.:J40,DC,3.8EDO@;%> 3JGYP 8(T!L_E!='\IK6]5"9(57).-]9R5J<&
M!@I^OLD:JJP%_'?!]OU[?VXPM;W4'Z^HX(!=L <03GC[$RI&W&]C<^7PW6]3
M6M\W@);#*8!9!0JNTZ(>'_EM!TC 1![NP>#PS[-N_^287/:/^B>7![7!X:/,
MXO*D\V>OV^^>7)*CLV-R\E?GCZ.S3R>D<_[U:_?RLGM^1AYM;M^H'(,+HP)_
MDQQ7.U72J&]OM5:9SD,Q!BFNFV0]MD;JL2602 R*9!9/XM63&#Y)UW]ZWOM*
MUO.,C@,G0@6@/4T<8\_Z;!"6=XB>$A+OA7> JWLG9WW2.[DX[_4?AX5!F\L(
MNA,5D$OF8":#0)APWB/V]H;[G@1#HL8,FR+!%0?H)Q #47_$R)&CL-EN-;=>
M+IG07. J>RR$J(IL))\9!6/!I"+L"MXB0C<S]WU[)6$P6:,/%3Y5;1?M+G0:
MNW0V@V&97R8L%]I.G1C[I;GG++@RQMS>V20X<+D,/3!A%!UXC P" >;Q0Z4.
MD23SO#C.2S_+D#K)Y_6I>,U=-89?ZV_CF5@>&ZJV#ACC!X*/QO&3B@Z8(:[&
MF/7P0 GXC!_=!+*9JS4(%/@P;1EXW"5V."6_U?6?_2LF%'>H%S/)!*(SC\63
M2"' B(^@?G\B(.VQ$9>8N51GT*(9Z6/WO'/4.^X>;9+N6:=Z QOA,FL*TQ3X
M4V.R!*&_B+"[E^&-DRD%786H0-$5*0H(E42&S$'WV27<)UQ) MH-)%F\7[IF
M\/EB9JII;G\5K]7%2TN6D3$Q&FS4-PG^?;]/"DQ#8JXA9C:DN?/VP=EF346.
M6Q08C2@6BN *F2VOR8W\=7TG$& K])Z!CKDZ)A7:"5PCCL?,H]=@!E:3PQL$
MKXA#^VV&GQ;?OAM"-9XHH8IT..4>@Q? ?FJDUS&YO-=JM9XGUI^J>!2QWJ?3
M;IRO<+0$9$@ L7IC=[O9VMN[:POT%+"UH66=!(($X$\+\@^XT]+EVN%.M/N#
M3@@,(<_JHA)[=W=<_@25Q@;FK[B4CX5_5$#$L/]CHOY19*';NR0GD] +9I@O
M? 3DYY40.0NJK^[>LXBFGH89.W)=P:2,?WSA/K.U"6LVZN0R^!$QCWRCLS(S
M%M-W($C-K'/P*Q/HP*_GHA]<^R9/&OG^[(IZI:[CYKJ)B=7\V7@FVKJ=BPOH
MR;&R0*>W .DPGL]IV7S63!KFH%T$,"_O_WB8.LVMK?K>]BU)Q-74:QE'YK7K
MLPI]8XQAW!L*( T/J4?8E#F1XE<8#H,2!)C4=\E_> A4<-EZYFAE?#VF'GW(
MK.X\PX*\]^ZWO8:]"Q)_*(EB'@O'@<^(K^W^)GI@7H3*G$# 1S7VVV1C/<E
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M&>]F$ 3>@ *U84W3K.[[)K@"!L,0,?+C*$$BB5J[6UO[OY0?6@LMORI@\3H
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M5A=H]R@2,QZY"$P!N!G^%[=0,''%XVM5)A\RJ5VFF'*%D%P:,N"G,(;K)5-
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M["W7_1JTS3E(IAK>UY&BF-$&&$T<+RELQ*2!G[;)9=/D]-%U5JVS6862JNY
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MPL:9? Q%>IU_#NL[:]J6\WGC6^'X9/=L_]57=,R7$TG_YJ3>(?,XD?M<PKE
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MU*TUO;A.DZGHA9V3/'9OC,.I4Y V_EO\L\EY%K6OHZ2Y=AQQVUM$O!/>L\W
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M6)KC0*XQRS"W90*_/SM[%>(OO&->\NE\7K%D^?$HNLE1RW&"O5&$HER:)@_
MNL[67 4QV@:^.PA%HDG8-#TW:F\A' ';@HNL;"NRZ3J!MTQ$2(--2K45(RFB
M') COV+7@)BFLQ9P=0B5=NUM,I*?+I+B-F",U(']\%D'<U@U-YUK0A>K1VE"
M4BA5W+P[K(I-]W/H9XXL*=:]X/FECCXEL7:OH(QU3, P21]W%M*!%M+IQ[20
M3N\LI#L+Z7=40(A;2"[MY"GI8+!7?JY]S/;\FD7)#R7G>(N?]UD!6G&S,A;4
M1<AV+2(4PU==GVP5\$X#P"LP%GSR]]#V()5D$Q ;<.>HNPD7ERHW<,V)?;GO
M/U]"^(NK+$\4[,9)/+\K<<>D)HP"U[4A*J[,U![A+0>WM8"%;#*;#U$<G1TS
M57.RRC:H^$@0;SYOT;N)W:PQ0<F]128+1 #,?\N))7QO6#8GU1I($UEE'886
MB#V8'8M'?S\.NCK,DIGA];:H>(;*.!50=/VM*8M7.*V/!0UH @2E.D3@>YK!
M$9OIK)(BQ*A)@$'8D&?5JU$I)UK$?NI8JBD$D+.3G@L@<\)8CF (91\@AWEW
MY?VE+A<-XU/]@._#.([S5(()@S<9/ZNE:B8SFV,/0=21%)0098R+-C$V@YR0
MJ/XX.-9P"7$EKV1W]]D"5X/KW?*QM,OG6.D<NT84,K M$J*8UEF!;H*A9IY)
M_0D4*@N.F2YP/7K<4STB2]6J*@G?PL1(&B$?.<S'9ND.)A[**]PAAKS,T>.R
M2<EJ2P-S:IM(PF5R9.84KBX[5J?)_^^$DI5(]+Q[>&ME@H:+K 8J+$]-Z 10
MZ5!8FK'49"NG$6XR;,F?<T](9L3J;)3%Y,][U$%F,YN&2:$!_)*FQY+=XH31
MD:(9ID-&?SJACQN/[;+U#-Y1;4Q?X!&P9V$R3UWNU[-L$WI8I&@.=6/R[;<;
MV_;K@1K)#["\EP;7=K[G_<]W/R5P"ET3&DPE64NXVS:I2^U?^ !@:M#N',(F
MQ):P!7F(_1Z!*8-M5RHAEU>L)K@'PX>A9@G8QGQQAAU I"+G/;L<4436S\J>
MV('2,!$4F\VQ- 3C]C#4?(GL0L9=V[0;DR]Z-$PSI9MR8])-A57R>)A.")J)
M]R:<S77]O#]!2AL061)K2NC:H-EA! EB]@O405EW/(!I458B3KZQ6^I[)K1&
M&"1(4%$* N\J\G01"GJ173<MB2)0$$K6/SY,HO?>&[W>BQ U=9_9"UQN=1\=
M\.YH$H/D'93L?)G<,R4%1:<1<S" 9E0N@V-$/HW67WDBN35X3TC$6$XJ9>2[
MYK!0!V?9P[6^GC.SP[H7K$@Y"JILFR=Q5'[H[3;6"**;BQ6S?[&-Y:TGO18%
M<K-;\CG1VQN9&:A3+/)"\3K.0/*[+ +-$7I@D4)+#+=%MG;8.:=LZALB.K!)
MT7+Z._^Y*T>+%5(#B_:N_6C ;XPQFJ!6;V)AP3O_W('^N0<?TS_WX,X_=^>?
MVZD-O]U+&R8].(-= <)9 E6L#+]LX-Z<L?=AA716SC;<0T%%0F60@[5S\Q@#
MT:A1/D5@V !?J1_ .88#J8<=M 1B0P-5F2I]WP@VMBPT>SH#2>KL3 *-%X+8
MPX"W_,J]H=59O2I7@4]I KPI&,,MBI?X8$8D_X)LPQDVD (XN"V:" ':SN%;
M1Z&GH-49,FA>.ZN3K04_'!^#+UN;[0$7-'*GPWVX:YN@!X/Y8%#[B-ZJXXL,
M=U<J+@IH.=@0,ZYA-@)=NH@<,I7IA]QEND(5W9L&CAXF"V,K?<W6$)I(,#<]
M![R=Y\=/+<7$F_H>AI2+O@R_=%D:?//K6P/ K#[B2+&P5(!43"4G)6IO.@30
M$=M<.?X,=Q]8@>2A]2-L7#47@F4,)]WYQAQ!V'@)8AM/SK/7QK><]@".TR-.
M<E3%8M0^;J8)N*[QU?Q\<G$R05LDL5(J3Q C]PIX9LU\4?#8_ZD>:M1=B2)8
M<IJT*K9+SW(_OLDNQ5]^A5[PG14(!J-4;J\TL:5OV&] OW;YE^D6 <F8[SO&
MKWWNR^K0S$BW6H=YC_8SJIFSBBMN*(VD,_"&(NY(Z!288#)PZH[]C\0HQE^D
M>_%0INX>]K>M=FD_J^.87017 W3?^&D'5//^,S7:V3#OIZ8D_-K.CIJ#N 76
M+0D&SE$07LB1Y&7A''QL,ESB#*OB*7/?A"+3.-8<$> 1" *Q_T3P8B5Q+2/3
MFB$XEPFOG!:<&(^47NDI%PW-HG#%Q3UYWA2=IG83ENS0A1-[/0K?-0FE-5?S
MR,E%7PQ@F_)T_(46I#D&VPDPAT1Z.I#Z)&]9\(])Q+-W*+R*^KIL&WTGK$Q?
MB L7S\Q*>5^OBJRBW"G,=%@4V"EXEFKB4#&,?F.^&]X6U M2GN6F<]+?EEO]
MV!R.?WG___) "7X>;(4?8,.0)-^IE)"G;UHQV5,1L7MS!?JZ(\GU>Q*/R=4:
MIE&WHSAKS!ZVS*;9<D9,3UG98D"B7638+=PI:<*VN_Q1,8<1/T VR$S_(O]2
M%I BC7I;B(>K8^V8:N-ADFR!02P-\;D(A?]XD<ROX+=SPF'SD#F3ER!WR""L
MY,I]\ZZ<LZSY9];FS9J87!4>"I_?9%U?C(@&?5C@'^YW>E)"J#2EZPZF,@V0
M$*,"!+ ,:XRNTAU"H9RNH\"^#<^GR+V1^@@Q;H*FS;!V(-K1#25U4_XU@X)Q
MA'6N/""17A-,^09=( A7KJHPMXOF+L?)9V%/_X".YCR-_&]0OT0(>1+>SG/S
M=A@_GA.20^-6G5Q*> 6['],E@@N'9,\4GM5T0*-.IRXGCYQ;^ ^8JN6ZNM1J
M<YRGIB!BOK\-.C1^)G7=GO#51[+2@]IA5J13;B3^3M.\../29WMD.8[YCE]N
M:Z%M"5LSMX_P>TY+ABG3P>'E>1AN0?Q\07?8<' 7")$#F_I3AB!X8%QTC0*<
M350\&MK'>=W'X/A3W#]_";_QPX_I-WYXYS>^\QOOU*+J [6HUSZZ_XJE<+Q"
M*1G"5HV"V["CTI+(,>;K-70#LFOA=1$!'S(*DG!<M8@3FZ:M5JTK D,@?*&E
M<]M#UG,U8T[.CF63;/?TZ*"-N+=6P._2_NT]ZAXQ:^(1$KM\S,8D#_/'/,LX
M,M 8]L:AMH1E!N>.K'S9Y+Z@DEQX@Q[>.:/L(6P./(1ORIZIW\X(&[?G"20]
MBNJ<,DLX\KB1(M13<^AM1JZE$I0':ISS5-EL'I1A)84*6]G:G*AJ'9G8$XTH
M L/[['E'.0AQ)&MF.+(T-+2W<.^ZT[H@+\>Q,/+B&>>2-=H-A^F@EWFR.SK'
M.A+.'AW^CHJ%+PB$H0&@=5<H C>GGQ,.T#"MCYJ>J&@8>LM9!]1!N 2?S,4
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MSC*X]>_]]*XJ-D_(SFU1-)UY"KVG*"J;6!7H_4(%NY@)I:%!5D24&#/H+2>
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MLR/+F]6XO*"4*QY-S5P=8X)WQU,/_;J42]LD7*L?CD3ZN#LIOO"Z;'LN_<>
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M-]$/GA5DYV+^PIL6!%&(CY&B31W:2&5W!:L\KXJL9?B(JT&W$UR%)@<S3IA
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ME"S%@.V)@),50X%CHC;D,I'5RU-C;614F<53[$AA7%= '1&(W75A"Z-ZY$\
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M82TR,#(S,3$Q-E]P<F4N>&UL4$L! A0#%     @ ZXEP5X)%/4*Z$@  97L
M !,              ( !D14  &)C9&$R,#(S,3$Q-E\X:RYH=&U02P$"% ,4
M    " #KB7!7C."#,/0)    +   #0              @ %\*   97A?-3DX
M,30V+FAT;5!+ 0(4 Q0    ( .N)<%=2+3*]Y(4  )#Y @ -
K  "  9LR  !E>%\U.3@Q-#<N:'1M4$L%!@     '  < OP$  *JX      $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
